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INTRODUCTION
It has always been the responsibility ot the
physician to aid the sick and to cure disease, and at
the present time this is being accomplished more ef
ficiently than ever before.

But not satisfied with

that, men of medicine have long tried to stop the rav
ages of disease. not only by treatment, but by prophy
laxis as well.

Many effective means have been used, and

a remarkable increase in the span of li.fe has resulted.
Until comparatively recently, chemotherapeutic agents,
as such, were unknown and with their advent, it was
natural that they should be used in preventing the dis
eases that they cured.

However, it was found that often

the chances were better in not acquiring a disease with
out the drug.;, than in escaping the bad effects of the
drug itself.

It is. obvious that there are certain qual

ifications .for an ideal prophylactic drug:
1. It should be completely effective in pre
venting the disease for which it has b&en intended.
Mere suppressive treatment is not desirable.
2. It should not harm the patient.

Allergic

responses should be minimal, and acquired sensitivity
should be impossible.
3. It should be effective against all strains
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of the organis�, and its use should not invoke the
production of drug-resistant strains.
4. It should be simple to give, with one dose
preferable to continued medication.
No drug satisfies these requirements.
is obvious at once.

That

How the present day drugs meet,

or fail to meet;., them will be taken up in this paper.
The current literature has been searched for reports
of efficacious prophylactic drugs and d.espite many "leads"
only four groups of d:rugs were found to have a •·present status":

the sulfonamides, the salioylates, "Bay

er 205", and the malaria drugs--quinine, plasmochen,
and atabrine.

The iittle known �Bayer 205" was one of

the first to be used prophyla�tically, and it most
nearly meets the ideal properties listed above.

Qui

nine, plasmochen and atabrine could almost be elimin
ated as true prophylactic drugs, but they will be con
sidered briefly because they have been used so exten
sively in the tropics.

The use of the salicylates has

been limited to the prevention of rheumatic fever re
erudesences but it shows promise of fulf1Uing en�ugh
of the requirements to be worthwhile.

The most con

troversial question of all is that of the prophylaetie
use or the sulfonamide drugs, and most of the space

,.
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will be used in consid�ing this problem.

The question

is by no means a closed one, and a study ef the reports
that have come in so far should be an interesting one.

PROPHYLACTIC USE OF THE SULFONAMIDES
INTRODUCTION
It should be admitted at the onset that the
following discussion on prophylaxis is limited to the
oral use of the sulfonamides.

A rather extensive re

view of the literature has been made on that phase of

the subject while the local application of the sult'a
drugs is mentioned only in connection with the sen
sitization problem.

The plan of presentation is !irst

to discuss the use of the drug in various diseases, and
then to evaluate its value in each.

The objections

to the prophylactic use of the sulfonamides will then
be taken up separately, and after the material has been
presented and evaluated, the "present status"· will be
given.

The conditions in which the sulfa drugs may be

used in prophylaxis are:

animal streptocoooic infec

tions, puerperal fever, scarlet fever, upper respiratory
infections, rheumatic fever, meningoeoceic infections,
gonorrhea, chanoroid, pneumococcic pneumonia, bacillary
dysentery, and seeondar7 infections of ·wounds, burns.
or surgery.

Conditions which also have at some time

been investigated for the effioaey· of the prophylactic
use of sulfa are tuberoulosis and virus diseases.
But no matter how efficient the sulfonamides
are in prev�nting any or all the diseases listed above,
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they have certain possible defects which will be dis
cussed under "toxicit.ytt , "physiologic effects", "sen
sitization", and "drug-resistant bacteria".

At the

end of eaoh section, a statement will be made as to
which way the present
points.
- available information
.
The work with the sulfonamides falls into
three distinct periods, (1) animal experimentation,
(2)

clinical studies among civilians, and

phylaxis in the armed forces.

(3)

mass pro

The final reports of the

last have of course not been released, but even with
those available at the pr-esent time, certain con
clusions may be reached.

Some extremely significant

series ought to be reported soon and they are awaited
with interest.
sent status".

Until then, let us consider the "pre

STREPTOCOCCAL INFECTIONS IN ANIMALS
In his original work with prontosil, Dog.
me.gk ( 1935 ). discovered its action against the hem
olytic streptococcus.

It came about through a meth

odical and systematic study of various substanoes,
notably gold compounds and certain dyea.

The former

did not seem to hold much promise, and neither did the
latter when tested against streptococci in vitro.
Despite this fact, one of these, prontosil, did show
a fair action in mice infection,.

First, Dogmagk ·

isolated a highly pathogenic streptococcus hemolyt1ous from human .infections, and inoculated a series of
mice intraperiton�ally with 0.5 cc of 1:1000 culture.
One and a half hours later, varying doses of prontosil
(0.02 to 10 mgm) were given subcutaneously.

All those

receiving the drug were still alive eight days later,
while ten of the thirteen c ontrols died the first day,

and by the third day, all were dead.

He concluded that

the streptococcus of erysipelas, as well-as that from
chronic infections were suseeptible, but that the ef
fects of the drug on staphylococcus and pneumococcua
should' be studied further.

Prontosil only worked in

living organisms, and as a therapeutic agent held
forth gr�at promise.

As f-ar as the toxicity was con-

8

9

cerned, he found that one-tenth to one-fiftieth of
the tolerated dose for three to five days after in
fection protected most mice and that some less acute
infections could be controlled with 1.0 per cent to
0.2 per cent of the total dose.

That was a good mar-

_gin of safety.
Another German worker, Horle1n (Editorial
1935} repeated similar experiments and found that all
mice protected with prontosil lived through strepto
coccal infections.

French scientists (Levaditi and

Vaisman 1936) corro�orated the finding that the drug
unquestionably provided protection again�t experimental
infections in mice in the doses used.

A more detailed

analysis was carried out by Buttle, Gray, and Steven
son in England (1936).

Prontosil and paraaminoben-.

zenesulphonamide in suspensions of gum acacia were
given by mouth to mice of 19 to 22 grams weight.

Then

the efficacy of these sulfonamide drugs· was assessed
by two criteria:

(1) an estimate of the number of

average lethal doses of cocci against-which the drug
would protect when it was given to infected mice under
optimal conditions for its action; and (2) by an es
timate of the latest time after infection when admin
istration of the drug would still be operative in
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saving the animals.

Paraaminobenzenesulphenamide was

found to protect mice against 10,000 l�thal doses of
streptooooci, but if one million lethal doses were
used, the mice died at the same time as the untreated
ones receiving one lethal dose.

Protection could be

demonstrated if eight hours elapsed between the in
��otion and the administration of the drug, but if
the drug was delayed until nineteen hours ai'ter the in
fection, only one out of six mice were saved, but
death was delayed.

They found that protection could

be obtained equally well agatt\Bt streptococci of dit-·
ferent serologie types.
Colebrook (1936) varied methods a little,
but arrived at the same conclusions.

Subcutaneous

injections of 50 mgm of prontosil in a 10 per cent
aqueous solution were given to mioe, which four days
later were given a dose of streptocoeoal culture into
the peritoneum.

No toxic effeots of the drug on the

mice were noted at any time.

0:f the untreated mice,

nine out of twelve died in three days.

Of the treated

-mice, two out of twelve died in thl-ee days, with two
dying later.

When the surviving animals were later

killed, there was �ound a larg� deposit of undis
solved pront.osil at the site of injection, and it
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seemed probable to the investigator that the prophy
lactic effect shown was due to slow absorption from
this depot.

The urine had an orange color during the

whole twenty-aix hours after the mice received the

drug.

In using Prontosil Soluble, it was found a lit

tle later (Long and Bliss, 1g37) that a single pro
phylactic dose administered to mica subcut,µieously
twenty-four hours prior to infection by the intraper
itoneal injection of from 100 to 1000 minima� lethal
doses of beta hemo1ytic streptococoi was ineffective
in protecting the mioe against inf'ection.

This result

was expected, because of the rapidity with which the
drug was excreted in the urine.

It was evident that a

certain concentration of. prontosil in t�e body must
be reached either at the time of infection or within
a definite time thereafter.

This could be accomplished

by prod�eing a reservoir of a slowly absorbing sulfon
amide compound, or giving a dose of a soluble drug a

short time after the infection.
In 1939, even after the clinical usefulness
of the sulfonamide drugs had been proved, Hoare (1939)
decided to run a controlled series of experiments to
check the 'previous experiments on the protection of
mice injected intraperitoneally with hemolytic strep-
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toooocus.

The newer preparation, sulfanilamid.e, was

given in 10 mgm doses three hours before infection.
Death was only delayed from twenty-four to fifty-one
hours in the protected mice over the control mice.

In

trying larger single doses, it was found that 30 mgm

produced toxic symptoms, incoordination, and muscle
spasms, but recovery followed in six hours.

Besides,

a single dose three hours before infection never gave
complete protection.

As a result, Hoare thought th&t

it was obvious that more than one dose must be given,
and perhaps he could have had better results if the
infection and drug had been given together.
out two series.

He worked

Series A contained the mice that r••

oeived a s�ngle dose of eulfanilamide two to three
hours before infection, and then multiple doses vary
ing from eight to twenty hours apart.

Series B did

not receive the initial dose, but the difference be
tween series A and B was never obvious in protecting

the mice.

He also performed experiments that showed

_that the tissue concentration of the drug must be main
tained for period if beneficial results are to be ex
pected.

Subcutaneous infections of 30 mgm of G and B

693 (2 ( p-aminobenzenesulphonamido) pyridine) in a
4 per cent solution of gum saline afforded complete
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protection, but oral administration was less satis
factory, probably because of faster absorption and
excretion.
PRESENT STATUS
Th� experiments with laboratory animals
have paved the way for the clinical use of �rophy
laetic sulfonamides by offering proof that suff1eient

doses ot the drug can protect animals against lethal
inoculations of the hemolytic streptocoeoua.

PUERPERAL PEVE:1-{

The first attempts of establishing the use
fulness of the sulfonamide drugs as a prophylaxis against
human diseases were faltering and somewhat vague statis
tically.

0n October 3, 1935 ., Professor Horlein of

Dusseldorf told a group of investigators in England {Ed
itorial 1935) that there were 1500 case records in Ger
many of acute infections caused by hemolytic strep
tococci ., including puerperal fever ., in which therapy with
prontosil w as strikingly successful, but he gave
no exact figures.

That the dreaded disease, puerperal

sepsis, could be controlled gave hope to obstetricians,
and a few trials were :nade to give the drug early
enough to prevent the infection from teginning in
postpartu,.-rn w omen (Colebrook 1936).

Even though it wa.s

realized that only those cases caused. "Jy the hemolytic streptococcus were affected, the cases w ere not
selected by the criteria of the causatj_ve organism .,
but usually a.t random.

Colebrook (193'1) reported on a

series in which the preventive policy was adapted.
Since he knew that the effect of pronto3il only lasted
for six hours, in a case of labor the initial dose was
given some hours before delivery and then repeated
evel'Y six :hours until the placenta was expelled and
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then at eight to eighteen hour intervals for three or
four d ays.

He obtained this plan from the results of

experiments on mice, but he had to chnnge the dosa,..·e for
human beings.

he decided to give one gram of' prontosil

or sulfanilamide three tines a day.

The blood from a

person receivinf_: such doses was f01md to destroy several
thousand s of virulent hemolytic streptococci, whereas
before only ten to forty were killed by the same amount
of blood.

Colebrook (1937) condemmed the use of the

d rug in cases of normal childbirth, and for cases with
obstetrical n1nterference'1•

'rlie only rational use, he

concluded, was in preventing the hemolytic streptococci
(proved by smear to be present) from gaining a foothold .,
since the optimum efficiency of the sulfas is felt only
if administered before tissue invasion has taken place.
Larger series were reported. ., but the results
cannot be evaluated because the caustive organisms of
the var:'Lous cases of puerperal sepsis were not reported .,
and the conclusions are not clear cut.

Johnstone (1938)

reviewed the cases puerperal sepsis in a maternity de
partr;-;.ent of a hospital.

He used the years 1934 ., 1935 and

1936 as controls ., and then in 1937 he gave each
maternity case some sulfona..rnide drug.

Prontosil (0.3
)
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and proseptina.sive (0.5 gm) were gi,:en to alternate
patients, two te.blets three times a day for the first four
days after delivery, and then one tablet three times a
day.

A few patients received one tablet (0.3 gm) of

prontosil three times a day all the time.

Parenteral

doses were given in addition when there was a high
probability of infection.

The results were:

(1) Loeal uterine infect:lon, i�e. offensive
lochia, uterine tenderness, delayed involution and
pyrexia.,
Infected cases

Total cases

Per cent infected

s.2

1934

165

1991

1935

19

2016

1936

3

2188

1937

139
15

2241

0(2) Llorbid puerperia, by B.K.A. standards,
due to uterine infection.
Cases
infected

E er cent
infected

1934

77

3.8

1'035

74

3.6

1936

67

3.1

1937

44

1.9

Another series carried on by Johnstone

(:i.bid) with M & B 125 was less nro:mlsing.

This drug,
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e

ivalent to pros

tinase, was used on alt ernate cases

in the mat ernal department of the Western General
Hospital.

The compar

ons between the ,::ontrol series

could not be strict, how'3ver, for the worst cases wer•e
always put on the sulfonrun
•

tablets wePe given four times

Two half

per day for the first four days and then one tablet was
for the next t hree days.

s a

•

322 patients received the sulfa
showed morbid puerperia, only six
in-fection.

The results:

•

total for the week, then was 20.5

The

Of these, 22

om local uterine

In the control series there were 383

patients, 15 of whom showed morbid puerper
only six from local uterine in±'ection.

, with again

The general

result seemed negative in this investigation.
Somev1hat the
and Sams (1933).
post-partu.rr.

San'.'e

methods were used by Ha.yes

t heir invest

ation, all emergency

patients received prosentinase Drophyla.c-

tic ally, ;,,::et t

for four days.

0.06 to 0.13

three times a day

There wc.. s a reduction of morbidity due

to 6enital sepsis from 22 per cent in 1935 and 17
per cent in 1936 to 11.5 per cent in 1937 when this plan
was used.

The criteria used for giving the drug was

(l) if the membranes were ruptured snd infection was
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potential or apparent; (2) if the patient remained in
labor for a few hours to a few days; (3) if obstetrical
shocl :: is present;

( 4) if multiple VRginal exams

or attempts at delivery were practiced; or (5) if the
case was terminated by means of an obE,tetrical oper
ation.

The number of cases was considered sufficient

to allow some significance to be put on the drop in
,�orbidity, and a standardized control series had been set
up.
I!oare (1939) realized that many more series
of cases would have to be carried out before the worth
iness of sulfonamide proph:rlaxis for puerperal fever
could be determined and although no such have been re
ported, their effectiveness in hwnan streptococcal in
f ections has been conclusively shown.

If the criteria

listed by Hayes a.nd Sams ( 1930) are considered befol'E,

the use of prophylactic sulfa, the ��rbidity of puerperal f ever would undou":Jt

c:rop •

PRESENT STATUS
The prophylactic use of srrall doses (viz,
one gram per day) of one of the sulfonamides will reduce
tt.e chances of postpartu..111 inf ection.

The effectiveness

of the r!rus is enhanced if the hemolytic strepto-
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coccus

is

the

medication is

offending

begun

shortly

a�ent,
after

ccntinued for at least four days.

and

if

the

delivery

and

SCARLET FEVER

Since scarlet fever is caused by a hemo
lytic streptococcus, it was obvious from the first
that

the

use of the sulfonamide drugs wo�ld be effica

cious in its treatment, and also in its prophylaxi.a if
proper doses eould be found.

Many doctors began to

give the drug to exposed cases and noticed its pro
tecting power.

One such (Laughlin 1940) reported how

in fifteen families exposed children were prevented
from catching scarlet fever with doses of prontylin.
The children were never isolated from the active cases
and some slept in the same bed.

The doses used ranged

from one-fourth tablet, four times a day for patients
one to six months old, to two tablets three times a
day for twe.lve year olds.

There were no controls in

this series, so these results cannot be evaluated.
The armed forces met the requirements of large
controlled series, and some very significant results
have been presented by them.

Studies in the Royal Can

adian Navy (Keith 1944) from January, to May, 1944
showed that there were 284 cases of scarlet fever in a
certain barrack block, with rather even distribution
during that time.

In one series, one thousand men lived

in three sections, two of which served as eon�rols with
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the other being given sulfad1azine.

In another series,

alternate men were given sulfadiazine and enteric coat
ed salt tablets.

No man knew which he was receiving,

thua avoiding psychological effects.

The drugs were

given in all cases at noon, and determinations were
made at different times to find what the sulfad1azine
blood levels with different doses were.

With the one

gram dose, at six hours the average level was 2.1 mgm
per cent and at twenty-three hours, 0.8 mgm per cent.
With 0.5 gm, the six hour level was 1.1 mgxn. per cent
and at 23 hours, 0.5 mgm per cent.
In the first series, the control sections
showed an increase of scarlet fever, while the third
had only one case the first week, and none the second.
In the second, more rigid series, the results were also
significant.

Among those who received the placebo,

there were twenty-six oases of scarlet fever and naso
pharyngitis, and in the sulfadiazine group there were
only eJght cases of nasopharyngitis and "none of scarlet
fever.
In the fall of 1942 (Watson, Schwentker and
Rothbard 1945) there oeeurred an epidemic of scarlet
fever among the personnel at a

u.s.

Naval Station, and

by N ovember of that year, ten new cases were appearing
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each week •

.On November 20, the whole personnel in one

school was started on 0.5
day.

gm ot

sulfadiazin& twice a

The results were striking, for the cases drc:>pped

to four a week, and then the next three weeks only five
cases appeared.

ln

the rest of the schools the inci

dence of acarlet fever remained high.

Then sulfadia

zine, one gram a·day, was started on December 11.

From

September 28 to December 18, ninety-five cases of scarI

let fever were reported.

From December 18 to January

8, there were no new cases, even though sultadiazine
was stopped December 22.

Even thougb there was no sig

nificant drop �n the �arrier rate,'the sulfadiazine !.!!!.
effective in controlling the scarlet fever epidemic.
Another example (Warren 1944) of the nice
series of cases that can be recorded by the armed forces
is that conducted with nine thousand men at the Army
Air For.ces Technical Training School, Truax Field, Mad'
iaon, Wisconsin. 111hree _grams a. week in one dose were
found ineffectual, and wnen one gram was given per day,
there was an erfective reduction in the incidence of
scarlet fever as well as other acute infectious diseases.
Painton (1944} reported that no oases of scar
let fever appeared at an army post after the routine
dose of one gram of auiradia&ine was given to each man
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each day.

In a general report, T. J. Carter (1945),

chief of the Division of Preventative Medicin�, Bureau
of Medicine and Surgery, said that in 1943 one million
Navy men were given sulfadiazine, and as one result,
the admissions for scarlet fever fell from 171.6 cases
per thousand men to 63.5 cases, in two weeks.

This re

sulted 1n the saving of many man days and muoh money,
totaling over one million man-daya for the medical per
sonnel and between fifty and one hundred million dollars
if the reduction in all the infections are considered.
If one wishes to evaluate a specific series of
cases, the following is quite suitable:

In 1943 (Co

burn 1944) a train�ng center with an average strength
of 43 1 000 had 4 1 973 oases of scarlet fever, which re
presented an esti mated loss of 108,908 man-dars of work.
In the middle of February, 1944, the scarlet fever rate
began to rise rapidly, and one half the- personnel of a
camp of 5000 men were given one gram of sulfadiazine per
day.

The results were strikipg.

The rate of incidence

on the day the drug was begun was 2.? cases per 1000 men.
One week later, the control group had 6 cases per 1000.
men, and the treated group, o.7 cases per 1000.

At two

weeks, the rate was 6.7 and o.-7, at three weeka, 2.2 and
0.3, at four weeks, 1.2 and zero, and at five weeks, 2.0

24

and zero respectively.
PRESENT STATUS
A daily dose of one gram of any of the soluble
sulfonamides, especially sulf'adiazine, is extrem41-y effective in protecting an individual from a scarlet fe
ver infectio�, the best results being obtained if the
drug is started a few days before exposure.

UPPER RESPIRATORY INFECTIONS
The etiology of most upper respiratory in
fections is undetermined but it is felt that a large
percentage is caused by a hemolytic streptococcus which
is susceptible to the sulfonamide drugs. When po·ssible,

the causative organism involved will be mentioned in
the following discussion.

In 1937, Smith (1937) noted that a group of
patients with hemolytic streptococcal tonsillitis went
into relapses from two to four weeks after complete re
covery of the primary attack�

Because of this, he gave

one or other of the available suli'onamide drugs pro
phylactieally in doses _of 0.6�3.0 gm for a few daya.
One patient actually developed a relapse. while having
small prophylactic· doses, but when the -d.ose was increased,
he recovered.

Smith concluded, "In a widespread epi

demic condition like streptococcal to�sillitia protection
cannot be gained by this type of prophylaxis.

This is

what would be expected when it is remembered that the

drug is rapidly eliminated."
Coburn (1939) in his work on rheumatic fever
{q.v.) noted that thirty highly susceptible ch�ldren 8
to 14 years of age remained free of hemolytic strepto
coccie invasion while receiving sulfanilamide.
25

In six
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out of ten who discontinued the drug there were later
signs of infection. This was an inconclusive report,
and it has remained for the military investigators to
offer the final proof of the usefulness of the sulfon
runides in the prophylaxis of upper respiratory infec
tions.
The urgent need of prophylactic control du.r
ing outbreaks of infectious diseases among military per
sonnel has led some medical officers to try small doses
of prophylactic sulfadiazine.

Warren (1944) found that

when 1 gm of the drug was given to 9000 soldiers there
was a significant drop in the incidence of certain acute

infectious diseases, among which was a nasopharyngitis
caused by the beta hemolytic streptococcus.· Painton
(1944) gave 6 gm of sulfadiazine to 18,000 army men and
found that the incidence of upper respiratory infections
dropped to one half for the follo•ing nine daya.
A few controlled series have been reported,
and it is expected that more will appear. However, the
res.ults so far are elear cut, and there is not much of
a possibility that the conclusions will have to be al
tered a great deal.

Keith, Ross, and Thomson (1944)

found that from January to May, 1944, there were 9?8
oases of acute nasopharyng1t1s in a certain barrack
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block of the Royal Canadian Navy.

Throat culture

samplings taken at that time showed 61 per cent eon-·
tained Group A streptococcus.

In one series, 1000

men lived in three sections, two sections being used
as contr�ls, and the remaining section given 0.51.o· gm of sulfadiazine per man each day.

In another

series, every other man was given the drug, and the
rest enterie coated salt tablets.

In the first series,

the control sections showed an increase in nasepharyn
gitis, whtle the treated section had only one case the
first week and none the second.

In the second, more

rigid series, the results were also significant.

Among

those who received the placebo, there were 26 oases of
scarlet fever (q.v.) and nasopharyngitis and in the
sulfadiazine group th�re were only eight cases of naso
pharyYlgitis.
Hodges (1944) foresaw a severe epidemic of
respiratory disease, and thus gave 2 gm of sulfadiazine
for three days to half the men at an AAP Technical
School.

The admission to the hospital dropped to be

tween one-third and one-half of the control group ad

missions.

Then the groups were reversed, and when the

same experiment was repeated the same str1k1� results
were obtained.

The most significant drop was in strep-
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toeoocal sore throat or follicular tonsillitis, th�
admission rate because of thes• oondit�ons d�opping
almost to zero.

The unexpected

beneficial results �f

sulf'adiazine prophylaxis on ordinary ref!p1rato-ry dis
ease was explained by the fact that a fair proportion
are bacterial infections.

Extensive laboratory work

was not available to prove this.
In the winter of 1944, Coburn (1944) used

sulfadiazine propbylaxia as the method of choice in

cheok1ng the dissemination of respiratory pathogens.
Controlled eJCPeriments were estab.lished in .t'ive largo

northern Navy training stations with high respiratory
disease rates.

A program was initiated in which there

was supervision of the distribution of the drug, ad
ministrat1on of cl1ni�al data, a cheek on ·the diag
noses of respiratory infection&• throat cultures taken
with infections, and a determination of the group, type
and drug fastness of the beta hemolytic streptococcus
encountered.

The re-.lts showed that the institution

of suli'adiazine p�ophylaxis, 1 gm daily, was strikingly
effeet, although Coburn did not give the figures.

As

a consequence of the favorable response, 250,000 naval
trainees were given the drug between December, 1943 and
April, 1944,.

The observationa indicate that the in-
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gestion of this amount of su�fadiazine daily is ad
equate to check a well advanced streptoooecie epidem
ic, to check a streptocoocic outbreak at its onset,
and to protect 85 per cent of susceptible recruits from
implantation with bacterial pathogens.

It was noted

that 0.5 gm sulfadia.zine daily is about 85 per eent as
effective as l.O gm daily.
A summary of the Navy's results (Editorial
1944 B) showed that when.600 1 000 men were given sulfa

diazine for varying periods between December, 1945 and
June, 1944 in doses of 0.5

gm to 1.0

gm

daily, a drop

of from 75 per cent to 80 per cent in siok call attend
ance for respiratory
diseases followed.
,

The s1_gn1f1•

cance of this in man-hours and money alone is astound
ing. At one Naval T�ainJng Center (Coburn 1944), there
were 50 1 000 cases of tonsillitis and pharyngitis in

19�2-1�43 with an estimated loss of 285 1 000 days
lost.

of work

Over 500,000 days o� work by personnel were spent

caring tor the inf'ections, with $5,000 1 000 sp�nt in sal
aries.

An additional $10,000,000 will probably be spent

in pensions for resulting disabilities.

It is clear

why there is much enthusiasm ?ver the bener�Qial·���

sults of sul.fad1azine_prophylax1a.1n the armed forces.
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PRESENT STATUS
The ingestion of one gram of aulfadiaz-ine
each day will greatly reduce the ehance of acquiring
an upper respiratory infection caused by the hemo
lytic streptococcus.

Epidemics of this condition may

be Qheeked by applying this plan to large numpers of
p.eople.

RHEUMATIC FEVER
Because of the observed frequeney with which
rheumatic fever recrudescences follow upper respiratory
infections, studies with the sulfonamide dr'0.8>soon after
they were discovere� led to their use in the control of
rheumatic heart disease.

As early as 19�8, Massell

gave prontylin to six rheumatic fever patients who had
positive throat cultures of the hemolytic streptoooo�
cus.

Six other patients were given aspirin and con

sidered as controls.

In both series, two developed re

erudesoenses and one died, and those receiving aspirin
were more comfortable.

Positive throat cultures stayed

for an average of sixteen days in the prontylin group,
and for eighteen days in the aspirin group.
It was observed early in the study of the' sul
fonamides that those drugs had little if any detect
abl� beneficial effect on the course of rheumatie fe
ver once the condition was well established (Swift,
Moen, and Hirst 1938) (Massell 1937).

Therefore, the

inv�stigators turned to the study of the effect of the
sulfonamides in preventing the hemolytic streptococcus
inf'ectiona which seemed to pave the way for rheumatic
fever attacks.· A preliminary report w�s made· by Thom
as and France· (1939) on patients who had had one or
31
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more major rheumatic ep1aode (1.e. confined to bed for
at least a week, with fever, polyarthr1t1a, aotive
earditis, chorea, or other signs}.

They gave the

pat�ents a gram of sul.f'anilamid� in three doses each
day from November, 1936 to Jun$, 1937, and 1.3 gm �•ch
day from November, 193, to June, 1938.

Amont 4i pa

tients, there was no incidenee of acute beta he�olytic
streptocoecie sore throats, or other acute infections
from that organism tbrough9�t the period of treatment.
Five of them had cultures e� beta hemolytic streptococci
from the thPoat in 166 cultures. Among the controls,
one patient was hospitalized for acute stre�tceoec1o
infection, and ten out of 71 throat cultures were pos�
itive.

Not one out of the thirty patients getting sul

fanilamide the seeond winter suffered from a major at
tack of'aQut• rheumatic fever in months�of therapy, but
four out of nineteen control patients did.

It was re-·

eogn1zed by the investigators that this group of cases
was too small to permit definite conclusion.a- concerning
the efficacy of sulfanilamide in preventing attacks of
acute rheumatic fever, but the results were encouraging
and warranted further studies along this line.
A few pessimistic reports have been sub
mitted, and they shall b& discussed now, and then in
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the final analysis the results of all experiments will

be considered.

Stowell and Button (1941) were scared

out of the prophylactic use of the sulfonamides be
cause one patient died from what was attributed to. be
the fault of the drug.

Despite this, seven patienta

did not have rheumatic recurrences.

Messeloff �nd RDb

b1ns (1943) have reported a series of eases in which
sulfanilamide was given in daiiy doses of 1.2 gm to
twenty-five ambulatory children and as controls, thirty
children with rheumatic heart disease were observed
without sulfa.

Two periods of prophylaxis of eight

months each--September, 1939 to May, 1940 and Septem
ber, 1940 to May, 1941.

The results in the treated

group were two deaths, one from congestive heart fail
ure and ene from acute bacterial endocarditis, and one
rheumatic recrudescence.

In the control group there

was one death from congestive heart failure and two re
crudescences.

So, in these series, the use of the sul

fonamides did not appear to be of value in preventing
rheumatic recurrences.
Coburn and Moore (1939) were led into their
work by the observation made by others, that rheumatic

subjects who escape hemolytic streptococcal infections
also escape rheumatic episodes.

First, they eotd"irmed
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the effects ot sulf'anilamide in guinea pigs with str�p
tocoecal lymphadenitis.

In seven weeks, fifteen anim•

ala which were treated with sultanilamide had no ad-�
enitis, while thirteen out of fitte•n con�rols did.·
�thermore, the drug appeared -to give complete pro

tection to a colony ot gumea p�sa against spontaneoue
lyap}ladenitis with group.a hemolytic streptoeocous.

experimental pharyngitis was given to pigs prote�ted
by the sulfa, whie� afforded about two-thirds protection.
A direct eompariaon was drawn between these infections
and h�an pharyngitis, and so, four series of oases
were set up.

The first concerned rheumatic subjects

who reported hemolytic streptoeoocic infections.

If

this was done less than twenty-four hours before the
onset, sulfanilamide was given, otherwise, the patients
were used as controls.

Three fulminating recrudescences

appeared, two in the sulfa group, and two in the control
group.

Six severe cases appeared, two 1n the sulfa

group and four controls.

In the second trial, twenty-nine rheumatic

gi1.9ls were giv�n two grams of a-ulfanilamide per day
for three doses.

Nineteen remained symptom free, silt

had vague symptoms and four had mila recrudescences.
In a third series with twenty-six children, twenty-five
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were kept in good health for months whil� taking two
grams of sulfanilemide per day.

One child became in

fected with a hemolytic streptococcus.

All the child

ren were constantly exposed to infection.

A fourth

group of cases presented the finding that when ten
children stopped taking the drug, six of them showed
throat infections, and three of these were followed by
rheumatic recrudescences.
In another report, Coburn and Moore (1940)
gave the results of studies on patients at a home for
girls who had had frank attacks of rheumatic feve� with
oarditis and could be under close observation.

Clin

ical observations were made each day by a nurse or tea
cher, and twice a month 'by the investigators themselves.
Sulfanilemide was given--three doses a day.

Most of

the girls received 3 gm daily, but some of the smaller
ones received 2

gm

daily.

Blood levels were maintained

at about 4 to 5 mgm per cent.

The authors concluded:

1. In at least ten families in which there
were outbreaks of hemolytic streptoooccio infections,

the rheumatic fever patients getting sulfanilamide es•
caped infection.
2. Upper respiratory infections with hemolytio
s.tPeptococcus were found ordinarily to have from a
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30 per cent to 40 per cent incidence in rheumatic fe
ver patients, but only a 5 per cent incidence in the
sultanilamide treated patients, using bacteriologic or
serologic evidence.

Approximately 6 per cent of the

treated group had a few hemolytic organisms in the
throat at some time or other w1.thout any evidence of
infection.
5. The incidence of rheumatic attacks in the

sulfanilamide :patients was low, only one out ot 184

subjects developed rheumatic fever with an ex.i-eoted
rate of 35 per cent.

The next two years after discon

tinuing the sulfa, the recrudescences of rheumatic
fever rose from zero in 1937 to five in 1938 and six in
1939.
4. In 129 unprotected pat1en�s, one half
showed hemolytic s�reptoeoceus infections during the
period of study.

There was a total incidence of 20

per cent recurrences of rheumatic fever.
Thomas continued her work (Thomas, France and
Reie.hsman 1941) and gave sulfanilamide continuously to
fifty-five patients with a recent history of acute
rheumatie fever during seventy-nine person seasons
between 1936 and 1940.

S1x�y-n1ne patients with a sim

ilar history who were given no prophylactic treatment
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were observed dur1ng_l50 person-seasons.

The drug was

taken_ds,ily from November to June, usually in a 1.2

dose.

gm

Fifteen major attacks of acute rheumatic fe

ver developed among patients not taking sulfanilemide
during the control period.
tween seasonal sulfa.

One patient had one in be•

'Besides this, five control pa-

tients had acute illnesses which might·have been of a
rheumatic character, one control patient was hospit
alized with an acute beta hemolytic streptococcic in
fection, and sub-acute bacterial endocarditis developed
in two controls.

In all, there were four deaths among

the control group, one from acute rheumatic fever, two
from subaoute bacterial endocardit1s, and one from an
unknown cause.

There were no deaths or major episodes

1n the treated patients.

Thomas {1942) decided that

sul.fanilamide should be started after a rheumatic ep
isode about a week before dis-charge fr� the hospital
in order to prevent a rapid invasion of organisms 1n
the throat.

She concluded this set of inveetigations

with the observation that prophylactic sulfa is ef. fective in preventing rheumatic recrude-_scenoes, is-.
relatively safe, and if the routine is stripped to the
essentials, the cost is fa� less than the cost of caring
for the cardiac invalids would eventual1y become.

She
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believes that every effort should be made to treat
every individual who has had rheumatic fever early in
the evolution of the di,ease with small doses of sulta,.
and to continue it over a period of years, in order
obtain real progress in controlling �heumatic heart
disease in this country.
Hansen, Platou, and Dwan (1942) added their
results to the mounting evidence in favor of the use

or the sulfonamides in preventing rheumatic recrud

escences, trying sul!athiazole and sulfadiazine as· well
as sult'anilamide.

The dosages varied from l to 3 gm.

Two series, comparable in age, sex, and severity were
set up, one protected with sulf'a, and the other not.
Their results:
Controls
Relapses
Pta.
1938-1939

4

1939-1940

13

8

1940-1941

21

10

1 mod sev.
5 mild

3 mod sev.
2 chorea
5 mild

Sulfa
Pts. Relapses
3

none

9

none

20

1 mild

46

1 mod sev.
(6 wks after
sulfa s"ttarted)

3 mod sev.
1941-1942

-8

2

1 mild

1 mod sev.

It was well established by that time, that
the use of the sulfonamides did not prevent the devel-

�
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opment.of rheumat�c recrudescenoea within a period of
two weeks a:f�er the first administration of the drug.
In the above series there was noted a favorable in
fluence on the degree of cardiac involvement, the
size of the heart, and the functional classif1oat1on
. by prophylaxis.

For example, in eight cases in the

control group, the funct1ona1 status was classitied
as being more favorable, whereas the status as regards
function was more severe in none, the same change in
gairi in weight, infections of the upper respiratory
tract, EKG, and general clinical observations.

The

same incidence o� anemia was found in both series, as
well as leukopenia.

There was a decrease in the poly

morphonuclear leukocytes in a few more treated oases.
A significant observation was that the patients getting
1.3 gm did as well as thoae getting larger amounts.
Kuttner (1942) reviewed the case histories
in a home for rheumatio fever children over a period
of years, and found the following:

In 1937, ·twelve

out of 108 children developed streptocoeoic sore throats
and follor.tng a latent period, s�x showed rheumatio
fever symptoms.

In 1938-1939, thirty-two of 108 chil

dren had streptococcio sore throats with no rheumatic
sequelae.

In 1939-1940, forty of 108 children had
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streptococcic sore throats and following a latent
period, eight of tqese developed rheumatic sequelae.
Eaoh year the type of streptococcus was different.

In 1940-1941 and 1941-1942, two groups were formed,

one to receive sulfanilamide, and the other not. The
d�aage was to maintain a blood level of 1.5 to 2�0

gm

per cent, and so 1 gm was given to those ehiidren
weighing leas than 75 lbs., and 1.5 to 2.0

gm

to those

weighing more than 75 lbs., in tbree divided doses each
day.

The result over the two winters was that a total

of thirty-two streptoeoooic sore throats were found in
the control group, with twenty-three rheumatic fever
recurrences.

In the protected group there was only

one streptoeoccic sore throat with a mild rheumatic
fever recurrence. Fourteen children under the sulfa
regime were found to be carriers of streptocoecus.
Chandler and Taussig (1943) also noted that
• rheumatic fever can occur within the first two weeks
after �ulfonamide prophylaxis 1s begun.

In the winter

of 1940-1941, eighteen patients received 0.6-1.5

gm

of sulfanilamide a day, and· t�e only rheumati� oc
currence was noted within two weeks.
Dodge, Baldwin, and Weber (1944) have added
the last report on the study of prophylaxis of rh•u•
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mat1e fever in civilian patients.

Eighty-eight chil

dren and adolescents with quiescent rheumatic disease
were given l to 8 gm of suli'anilamide da;17 thrqughout
the winter and spring months for a total of 181 patient
seasons, and 101 rheumatic children were observed as
controls for 138 patient-seasons.

Dui-,ing the period

of the study there were in the control gr�up 54 Group
A hemolytic streptococcal infections, an incidence of
39 per cent.

There were nineteen definite major rheu

matic relapses with two de�ths, and
sible relapses.

seven mild

or pos

In contrast tq this, only five hemo-

lytic streptococcal infections occurred in the group
of children receiving suli'anilamide prophylaxis, an
incidence of 2.? per cent.

Two children, or 1.1 per

cent of the patient-seasons of prophylaxis, developed
definite rheumatic relapses while taking the drag reg
ularly.

Two other children died of congestive heart

failure without evidence of streptococcal infeotion or
active rheumatic disease.

Two children with recently

active rheumatic fever showed signs of 1nereas1ng rheumatic activity within two weeks of starting the drug,
but the remainder of this group of children remained
free of streptococcal infection and rheumatic relapses.
The experments so far presented have been
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summed up in the chart below, and the total results
analyzed by the Chi square teat.

The probability that

the drop in rheumatic recrudescences in the patients
taking sulfa is due to chance is much less than l in
100,000,0001
Our Army and Navy do things in a big way,. and
their work on the prophylactic use of the sulfonamides
is no exception.

Figures such as hav� never been seen·

before in series have been offered for analysis in
evaluating the value of the daily ad.ministrations of
the newer sulfa drugs, especially sulfadiazine.

Dr.

T. J. Carter, chief of the Division of Preventive Med
icine, Bureau of Medieine and Surgery (Carter 1945)
has.s�id that all naval training stations carried on
"the largest controlled experiment in the history of
medteine," when in 1943, one million men were involved
in a controlled mass chemoprophylactic program.

The

incidence of rheumatic fever in some places has been
reduced from 87 admissions per thousand men to zero
in four weeks.

The individual reports of the military

experiment, as many as have been released, will now
be considered,
Sulfadiazine in a prophylaetio dose of 3 gm
one� a week given to 9600 men at an Army Air Forces
Technical Training School, Truax Field, Madison. Wis-

CHART I
Patient- Rheumatic Patient- Rheumatic
seasons R&lapses seasons Relapses
Control
Treated
( l)

( 2}

6
20

(3) 150
(4) 129
(5) 14
(6) 46
( '7) 108
(8) 17
{9) 138

To:tal

627

2

11
15
27

4

21
23
5

19

HM

6
20

2

. 102

114
184

l

7•

0
2

78
108
16
181
'714

l
1

4

23

Dose
Per Day

3

2.6
2
4.5
1-5
1-2

.6-l.5
1-2

gm
gm
gm
gm
gm
gm

*one death from drug
Investigators

Year

Massell
Coburn and Moore
Thomas
Coburn and Moore
Stowell and Button
(6) Hansen, Platon & Dwan
( 7) Kuttner and Reyersbach
(8) Chandler and Taussig
( 9) Dodg�, Baldwin & Weber

1937
1939

·{ 1)

(2)
(3)
(4)
(5)

1939-42

1940
1941
1942
1943
1943
1944

Summary of results in giving small daily
doses of sulfonamides to rheumatic children. The
number of rheumatic relapses decreased from 20.2
per cent to 3.2 per cent with the medioation, and
if the earlier series were not counted, the re
duction would have been even greater. The chance�
that these figures came about by chance is less than
one in a hundred million.
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consin, proved to be ineffective in reducing the in
cidence of acute infectious diseases, but in proph7lactio doses of 1 gm, a definite effect was also noted
on the incidence of rheumatic fever oceurring at a
later period than the effect on acute hemolyti.c strep
toeoccic disease.
Col. Holbrook of the Ar-my Air Forces has re
viewed the incidence of rheumatic fever (Holbrook 1944)
and even though total figures were not available, it
appeared from "considerable data on hand that the re
duction in rheumatic fever parallels the reduction in
respiratory diseases and streptoooecic infections" in
men given 0.5-1.0 gm of sulfadiazine a day for a short
period.

Coburn (1944), now in the Navy, ha� continued

his work with the sulfonamides, and has reported his
results in checking an outbreak of virulent hemolytic�
str�ptoooccus among 43 1 000 men in a training center.
The drop in the incidence
organism was

or infections caused by that

followed in two or three weeks by a

striking drop in the incidence of rheumatic fever.

Only

the preliminary report has appeared thus far, and so
t-li�re is no data to analyze. •
Thomas (1944) �also has taken the opportunity
that the military services have offered in the way of
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huge controlled series.

She has analyzed the results

when :prophylact1o �ul.tadiazi:ae.,. uauall_y .1

a day t.
was administered to part 0£ the personnel of several
training centers from Dec.

r,

gm

1943 to March l, 1944 .,

with other groups at the same centers serving as con
trols.

Abput 250,000 men were taking the prop�y�actic

medication, and aQ equal number were obs�ved as con
trols.
Week of Prophylactic Sul;fadiazine Administration
Attack Rate of:_
Rheumatic Fever

1

2

3

4

5

87

45

45

19

6

Scarlet Fever

70

45

0

0

0

The cb�rt shows the incidence of rheumatic
fever and scarlet fever 1lluatra·ting how thet"e is a
lag in the effect on the fo�er disease with sulfa
prophy1ax1th

This led Thomas to renew h-t»" belief in

the coneep_t t}la.t acute rhewnati.o fever is usually pro
duced by sensitization to the beta hemolyt.ic strep
toooecus.
All that has been men--tioned in thf_tl. pre
sentation of the contPol of rh�umatio f&ver i,a the

administration of the sulfonamides, put �t must be
remembered that it is only part- of the program to
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sai'eguard the welfare of rheumatic patients.

The fol

lowing (Thomas 1944) should be carried out for the best
results:

First, the patient must be in the best phy

sical condit!on, with adequate diet and general sup
port; second, the dose of 0.5 or l.O

gm

of sulfadiazine

preferably should be used continuoualy under constant
supervision, with rashes reported immediately, and blood
studies should be made at regular intervals.
PRESENT STATUS
,

In patients who have suf'fere� from one or

more Rheumatie Fever attacks, the daily ingestion of
one gram of �ulfadiazine is extremely effeeti.ve in
preventing reerud$seences.

The medication may be

started about a month after a rheumatic ��sode and
continued indefinitely; a common plan is to give the
drug during the winter months for five years.

There

should be monthly oheek-ups on the patient's progress,
and. the usual control measures s�uld not be di5•
continued.

MENINGOCOCCIC MENINGITIS
The control of me-ningocoecie meningitis re
solves almost completely into the elimination of car
riers, which result after many cases of the infection.
The ordinary means of detecting carriers and then iso
lating them becomes quite tedious, and when the sulfon
amides were found to be effective -against the menin
gococcus, they were given to carriers, potential or
actual.
From November, 1937 to March, 1939 there were
thirty cases of eerebralspinal meningitis in a found
ling hospital in Australia (Meeham and Merrillees 1940).
General hygienic measures and local applications failed
to prevent new cases, and seventy-five oarriers were
discovered by swabs.

These were treated with M & B

693 and seventy-two throats became negative, two neg

ative smears being required.

Even with the observed

relapse of carriers, the sul.fonamide was effective in
reducing the carrier rate below the danger level.

The

dose decided upon was one gram per 14 lbs. bodyweight
per day, given in four doses.
A somewhat different procedure showed equally
good results (Fairbrother. 1940).

Routine swabs 1n a

hospital were taken of all patients, and the results
46
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were:

139 patients were being treated for gonorrhea

with sulfapyr1dine, and only one of these showed posi
tive nasopharyngeal smears for the m-eningoeoocus.

Close

contacts, but not treated, showed twenty-two positives
out of 135 patients.

A group of 154 non-contacts, not

treated, showed 33 positive smears.

The poss 1b1lity

of a cross-immunity was ruled out as a eause of the
decreased rate of i ncidence of the men1ngocoeci by a
previous r�port (ibid) of a meningeal carrier rate of
48 per cent in f.itty cases of gonorrhea.

Therefore,

the decreased incidence of carriers was a direct re
sult of the sulfapyridine, the authors concluded.
Reports have �hown that nearly 100 per cent
of eases of cerebral spi nal meningitis become chl'onic
carriers (ibid).

In 14 patients recovered from men

ingitis, swabs were taken fran 17�76 days after onset of symptoms in which chemotherapy had been success
fully applied, and no meningoeocci were found.

This

has given some support to the view that intensive sul
fonamide therapy removes meni ngoGoe�i from the naso
pharyngeal mucosa.
The same investigators (ibid) tried a final
experiment in which only sm�ll. doses of sulfonamide
drugs were given to eliminate known carriers.

Four
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grams of sulfapyr1dine were given on two days, and then
three grams were given for two additional day�.

Thir

teen out of thirteen cases became negative.

Another small aeries (Strong and Blumberg
1943) indicated that sulfathiazole was more effective
in eliminating carriers than sulfanilamide.
doses (6

gm

Large

per day for five days) of sulfapyridine

succeeded in ridding the nasoph-arynx of meningococci
from. all of thirty-five carriers, while the same amount
of �uifanilamide only es.used twelve out of seventeen
carriers to become negative in five days.
The final proof of the efficacy of the sul
fonamide drugs in eliminating carriers was given by
the armed forces.

In World War I, meningocoocic men

ingitis was the fifth cause of death among enlisted men
and was fatal in 38 per cent (P�inton 1944).

In World

War II, ehemotherapy has kept the mortality rate as
low as 2.5 per cent, but there are still sporadic out-

.

breaks which may turn out to be dangerous.

In men-

ingoooccus infection the problem resolved itself into
the elimination or isolation of the carrier.

The rate

of carriers among contacts is 20 to 40 per cent, while
in general army life it is about 4 per cent (ibid).
New recruits are especially apt to be carriers.

It
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was found that extensive carrier

determinations made

during epidemics and wholesale isolation of carriers
were relatively 1neffect1�e during the first World War.
The determination and isolation of carriers is not a
simple one and for most army centers is 1-mpractio able
because of the tremendous work involved.

Thus, some

other means of control should be worked out, and both
toxins and vaccines nave been tried for the mass prophylaxis of meningococcus infections with inconclusive
results.

Sulfa spray and swabbing of throats have also

been indifferent in effectiveness.

Oral sulfa alone

showed promise.
From January 1, to April 30, 1943, there were
more than 1300 cases of meningococcio meningitis in the
military personnel of the Fourth Service Connnand, and
ordinary measures showed no signs of controlling them
(Kuhns, Nelson, Feldman and Kuhn 1943).

Studies at

the headquarters laboratory showed that the meningoeocoi
are rapidly eliminated from the naaopharynx following

the oral administrations of one gram ot sulfadiazine
three times a �ay for three days.

Cultures were found

to remain negative up to eight weeks in some cases.
With this hopeful beginning, a clinieal te-st was made
in two forts.

In Fort A, one gram of sulfadiazine was
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was given three times a day after an epidemic of men
ingoeocoic meningitis had started.

During an eight

week period �f observation subsequent to the completion
of prophylactic th•�apy, no cases of the diaease devel
oped among 8000 men. At the same time, although the
attack rate exhibited a definite decrease, 23 oases were
found among the 9300 untreated controls.

{ibid)

At Fort B, an eight week's observation re
vealed two cases of meningitis in treated men, while
seventeen were found in the control group.
two grams- for two days.

The dose was

(ibid)

In Camp! the effect on the carrier rate was
strikip.g.

Percent positive
Throat cultures
Treated ------ Controls

March 20 - 21 .
(before treatment) • •

• • 36 • • • • • • 38
March 31 - Aprill • • • • • • 3.1 • • • • • • 30
April 7 - 8 • • • • • • • • • •

2.1 • • • • • • 57

• • • • • • • 2.0 • • • • • • 51
Apr-il 21 - 23 . • • • • • • • •
• • • • • • 57
May 20 - 31 • • • • • • • • • •
• • • • • 56
April 14 - 15 • •

Another series :from Fort B showed a similar
drop in the incidence of carriers.
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Oral sulf'a was also used by Painton (1944)

with brilliant success in controlling meningoooooi
carriers.

In May, 1943, eighteen cases of meningo

coccic meningitis appeared in rapid succession at an
army post.

On May 21, about 18,000 trainees and per

manent party men were "diaz1ned 0 with five grams of
sulfadiazine within eighteen hours.

After that, no

other cases of the infection were hospitalized up un
til the report was written eight weeks later.
The use of small doses of sulf'adiaz1ne in
controlling epidlltnics of meningQcoccis men1ng1tis has
been thus indisputably proved to be an effective means
or protecting contacts from either acquiring the disease
or becoming carriers.
PRESENT STATUS

T�e meningoeocci may be eliminated from the
nasopharynx of carriers by the ingestion• of sulfa. diazine, one gram three times a day for three days.
The same procedure can also prevent clinical meningo
coccic meningitis from appearing in almost all exposed
cases.

GONORRHEA-

In spite of vigorous campaigns with the well
known methods of prophylaxis there have alway� been some
cases of gonorrhea in the armed services.

The substi

tution of the sulfonamide compounds for other local ap
plications may have increased the percentage of "cures"
(Stedman.1943) but it could not of course help those who

do not report soon after exposure.
uation aboard the

u.s.s.

That was the sit

Houston in 1941 (Joses 1942)-

the sailors were uau�lly inebriated when they returned
- to the ship and did not have the presence of mind to
receive prophylactic treatment.

A routine was then

initiated in which all men who had not used other means
of prophylaxis were given 3 gm of sulfathiazole at
0800 next day, then 3 gm at 1200 and 1 gm at 1800.

Of

the one hundred fifty men given this treatment, none
came down with gonorrhea, and later another series of
two hundred men were protected from the disease with 6
gm of sulfAthiazole given the next day.

On the

u.s.s.

Marblehead this routine was combined with other forms
of prophylaxis in four hundred fifty men and only one

case of gonorrhea was tound, that proving to be aulfa
resistant.
Kline (1942) reported a series of one thou-
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sand consecutive exposures to gonorrhea in the Navy
in which only one case of the disease developed 1n the
urinary tract when 2
fore the contact, 2
five hours later.

gm
gm

of sulfathiazole were given be

the next morning, and then 2

gm

Two cases developed in men taking

only 2 gm of sulfa.
In the army, two reports have been presented
concerning the control of

v.D.

in negro troops

less 1943, and Arthur and Dermon 1943).

(Love

Loveless tells

of a company of about fourteen hundred negro soldiers
who were given a sulfe.thiazole p.rophylaxia of 2 gm be
fore leaving the fort on pass.

Those taking the station

_prophylaxis received no further sulfath1azole, but all
others received 2 gm on returni)lg, and 2
morning.

gm

the next

In that company there was a phenomenal drop

in the gonorrhea rate.

Excluding "failures"---not under

the 1nf'luenoe of the drug at the time of exposure, the
gonorrhea rate dropped to a level of eight cases per
thousand men per year as compared with one hundred se
venty-one cases per thousand men per year in the control
group.
Arthur and Dermon (1943) said that they had
:found that among the negro troops they studied, the
usual methods ot v.D. prophylaxis i'ailed in a g�od
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number of eases.

Therefore, 152 men with 199 exposures

were given aulfathiazole the day after exposure, 3 gm,
2 gm and l

gm

after the meals, and 259 men with 385 ex

posures were used as controls.

In the sulfa-protected

group there were no cases of clinical ureth1t1s, but
eight men had positive ,rostatie cultures for the gon
ococcus.

The control group had fifteen cases of clin

ical gonorrhea.
The Navy in a survey of its experiments (Gooch
and Gorby 1944) said that at the time a sulfathiazole
pr()J>h.ylaxis plan was put into effect, the annual gon
orrhea rate of some military units averaged l'!O cases
per thousand men.

After two and a half months of ap

plication, the annual rate was reduced to an average
of seventy eases per thousand.

This "basic rate" is

due to those cases contacted on furloughs where no pro
phylaxis is used.

Two methods of prophylaxis with sul

fathiazole were used, one entirely local, and the other
giving 2

gm

of the drug be.fore and after exposure.

PRESENT STATUS

The chance of acquiring a olinieal case of

gonorrhea after exposure has been shown to be greatly
redubed by the ingestion of four to six grams of sul
fatbtl.azole or sulfadiazine within twenty-four hours af
ter the contact.

CHANCROID
The same reports that have shown a bene
ficial result on the rate of gonorrhea among military
personnel have also ind1�ated that the rate of in
cidence of chancroid inf'ections has also been fav
orably influenced.

In the Navy, Joses (1942) reported

a cessation of ini'ection �tter the sulf'athiazole pro
gram was introduced, and in the Army Loveless {1943)
showed a drop incidence from 22 cases per thqusand men
per year to six cases per thousand per year.

In a

smaller series (Arthur and Dermon 1943), 199 exposures
protected with six grams of sultathiazole given the
next day only p:rodueed one c·ase of chancroid ulceration,
and 384 unprotected exposures produced eighteen eases
of chaneroid infectio�. {See discussion on gonorrhea
for details on dosages.)
An experimental study was m�de to prove the
efficien�y of the sulfa drugs in preventing known ex
posures from developing chancroid (Greenblatt, Sander
son, Mortara, and Kupperman 1943).

Volunteer patients

were scarified on the thighs with virulent strains

or

H. duoreyi, and th&n given doses of sulfathiazole vary
ing from five to forty-two grams, start�ng it at the
time of inoc11lat1.on or before.
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Chaneroid lesions de-
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veloped in on1y one out of forty inoculated zones
(ten zones in each of four patients).

However, when

the same group of patients three to five days after
cessation of therapy were reinoculated, lesions de
veloped in all but one instance.

The authors felt

that thus sulfathiazole oould prevent ehaneroid
disease, and there seems to be little doubt that it
oan.
PRESENT STATUS
The chance of acquiring a chancroid i�ection
af'ter exposure is almost zero it four to six grams -of
sulf'adiazine or sulfathiazole are ingested within
twenty-four hours.

PNEUMOCOCCIC PNEUMONIA
The nature of pneumonia is such that the
disease would be hard to control with a prophylactic

drug, except 1n special oases.

One of these is in

preventing the plague of surgeons, postoperative pneu
monia. Several investigators• reports have been re
viewed by Hochberg, Hershenson, Winkelman, and R1okin

(1941), whieh point out that in large series of cases,
the incidence of pneumonia varied from 1.1 per eent
with 44 per cent mortality to .44 per cent with a 71
per cent mortality.

A third series with a .15 per

cent incidence of postoperative pneumonia had an 88
per cent mortality rate •
. Carefully conducted series in animals were
carried out to reach some decisions for the efficacy
of the sulfonamide drugs in preventing pneumonia, since
a need was obvious.

Gregg, Loosli, and Hamburger

(1959) (1940) reported unfavorable results in dogs,
concluding that lobar pneumonia could evolve-despite
the administration of large doses of sulfapyridine
before and after infection, and despite its presence
in the blood in concentrations equal to er greater
than those obtaining under conditions when the drug is
regularly curative.

Goldstein and Graef (1940) agreed
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with these results, but said it was dif£1oult to
state conclusively that the animals had clinical pneu
monia.
Superf'icially, the experim�nts of Hochberg,
et al, (1941) were the same as the previous ones cited,
but he observed that the other investigators gave the
prophylactic sulfonamide about eighteen to twenty
four hours before infection, and then again six to
twelve hours bef'ore.

The doses were repeated at six to

eighteen hours after the infection.

The long intervals

between pre- and postinfection doses did not allow the
full effect of the drug to be fully felt.

Besides, the

former experimenters killed their dogs 1n twenty-four
hours, thus preventing any further study on the out
come of the disease.

Hochberg (1941) took daily chest

x-rays of the dogs, and in those animals which re
ceived the sulfonamide>with but one exception, there
were never any signs of' postoperative pneumonia.

In

the exceptional case, the infection had subsided in
forty-�ight hours, and in· five days there was no his
tologie lung pathology.

The dogs were subjected to an

abdominal operation under anesthesia and then given an
intrabronchial injection of pnemnoeocci.

A series of

computations was made to determine all the possible
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factors, and th� results appear fa�tly significant.
Goldstein and Graef (1940) experimented with
pneumonia in rats and said that there was no progress

of the disease after t�ent-y-four hours in the animals
protected with sulfonamides, and there was no spreading
of the infection as in the controls.

Gross and Cooper

(1937) infee�ed twenty-seven rats intrabronchia.l.ly with

a dilute 24-hour broth culture of type III pneumocoeci
suspended in mucin.

Thirteen of these animals were

given 125 mgm of para-aminobenzenesulfonamide orally
immediatel7, and the other fourteen were unprotected.
Results:

23.l per cent of the protected rats and 85.7

per cent of the controls died within fifteen days.

Sim

ilar series (Rosenthal, Bauer and Branham 1937) in mice,
rats, and rabbits have substantiated the favorable re
ports of the prop�ylax1s against pneumococoi by the
sulfonamides.

It w�s found that the oral route was

best.
These experimental conditions could not be
imitated in.man and not until the army began to give
prophylactic sulf'adiazine to its men, were figures

obtained (Hodges 1944).

During the winter season

or

1943-44, l.0,000 men in an A.A.F. Technical School were
divided into two equal groups, and first, one half was
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given sulfadiazine, and then the other.

Short courses

of the drug were accompanied with immediate drops in
the incidence of pneumococci pneumonia, which, however,
rose between prophylactic periods.
found to be one gram per day.

The optimal dose was

The average drop was

from seven cases per- thousand men per week to one per
thousand, or even zero in some cases.
change

in the distribution pattern

of

There was no
the various types

of pneumonia.
PRESENT STATUS
The chances of acquiring a Jneumocoeoie pneu
monia may be greatly reduced by the daily ingestion ot
one gram of sulfadiazine.

BACILLARY DYSENTERY
The less soluble sulfonamides have been gen
erally used for bacillary dysentery, and there seems
to be no contraindication for those drugs in any gas
trointestinal disease in which there is no break in
. the continuity of the epithelial wall of the intestin
al tract (Scott: 1943).

In a certain dysent&ry out

break (Sonne) in a home for mental defectives (Yannet,
Deutsch, and Lieberman 1944). sulfathiazole was effective
in controlling it, but the drug did not shorten the
period during which the organism could be found in
rectal cultures.

Therefore, in a renewed outbreak of

the same condition two years later, sulfaguanidine was
used to reduce the length of the carrier state because
of its poor absorption.

A total of twenty-nine cases

occurred, with the Sonne organism being isolated in
each case.

Eighteen cases were given sulfaguanidine

for seven days, and eleven were given the drug for
fourteen days.

There was no difference -in the time far

negative cultu.Pes to appear in these cases and in the
group which received no spee1!1e drug therapy.

The

dose was about one-fourth of the usual therapeutic
dose, and th&refore propably inadequate.
A more optimistic but statistically unsound
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report was made by Imboden (1943) from an experience
on a trip to Mexico.

Three travellers took five grams

of sulfagaanidine H.S. and none had the slightest gas
trointestinal symptoms, while there was a 90 per cent
incidence of dysentery in fellow travell�rs, with sev
eral severe cases.
More careful studies have been made, and these
reveal a definite effect on the development of dysentery
cases by the use of sulfaguanidine.

An epidemic of

bacillary dysentery broke out in another school for
mentally defective children.

(Scott 1943)

The in

vestigators first evaluated how effective the drug would
be, and considered how the concentration of sulfaguan
idine in the bowel at any point anywhere will be de•
pendent on the dosage per unit of time and second on the
volume of intestinal content passing that point per
unit of time.

Since ehildren have about the same in

testinal volume as adults, no difference in dosage was
made.

Since in diarrhea the intestinal contents are

large, the prophylactic dose is smaller.

One half

gram three times a day was started on the fifteenth da7
for everyone.

Following this, one hour after sulfa

guanidine was started, one case developed but after that,
no more.

A record of cases showed that the total num-
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ber of oases dropped from twenty on the fifteenth day
of the outbreak, to none on the twenty-second.

Thus,

the outbreak was controlled in one week.
In a controlled series, 118 children were
confined to a hospital with scarlet fever when a dy
sentery outbreak occurred in one wing of the building.
Forty-five ehiidren were in the wing which was exposed,
and were given o.05

gm

sulfaguanid1ne per kilogram of

body weight every four hours for one day and every
eight hours for two days.

There was no dysentery in

any of them; one had slight fever with four stools
two days after the aulfagu.anid1ne was started, but no
mucus, blood,or dysentery organisms seen.

The other

wing was supposedly protected and no aulfaguanidine was
given, but in the next five days, four children con
tracted dysentery.

Twenty-nine children between two

and twelve years of age were treated, since all of
them had a fever and mucus in the stoois, and had dy
sentery bacteria isolated.

Twenty-five showed anti

bodies during their convalescences.

This shows a def

inite beneficial effect by the sulfagu.anidine.
PRESENT STATUS
Bac_illary dysentery infections may be pre
vented by the ingestion of

o.os

gm

of sulfaguanidine
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per kilogram of body weight every four hours for three
days after exposure.

EXTERNAL INFECTIONS
Wounds - Burns - Surgery
It is not within the scope of this paper to
discuss the local use of the sulfonamide drugs, even
tb.ough this has been a major innovation in the care of
surgical patients.

As far back as 1939 (Jensen, Johns

rud and Nelson 1939), the application of sulfanilamide
to sites of trauma was advocated.

At the present time

it has become almost routine to sprinkle one or the

other of those drugs into any surgical incision, open

wound, or compound fracture site.

The giving of sulfa

by mouth besides that; is often advocated, especially
if the region of contamination is inaccessible or
covers an extremely large area.
Burn wounds are usually contaminated, and so
if possible they should be protected early.

Cope

(1944) states that chemotherapy is indicated in all
except one and two degree burns where the blisters will
not rupture.

·In severely burned patients, 2.5 gm of

sulfadiazine is ·given intravenously and then the blood
level k�pt at 6 to 12 mg per cent until the epidermis
is firm enough te bar entrance of organisms.

With the

hope that che�otherapy with sulfonamides would reduce
the incidence of infection, the Cocoanut Grove patients
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at the Massachusetts General Hospital were given sulfa
diazine (Cope 1943). The blister fluid of these patients

was found t·o contain baoteriostatic �ounts of the drug,
and infection was not a serious complication in these
cases, but there were no controls.
The National Research Council (Meleney 1945}
reported a series of project cases that indicate that
the incidence of infections iri burns 1s not affected
by sulfonamide therapy.

General sulfa was given to 141

patients and of these, 19.9 per cent became trivially
infected and 31.2 per cent became seriously infected
for a total of 51.1 per cent.

Of the patients not

treated with the drug, 10.4 per cent were trivially in
fected and 24.9 per cent seriously infected for a total
of 35.3 per cent. The conclusion of the Council was
that oral sulfonamide thePS.py does not lessen the in
cidence of local infections in surface body burns •
. In this field of study, there is a distinct
need for series of cases with parallel unselected, un
treated controls under the same conditions as the treat
ed oases. The careful control and study of the re
sults of such work will alone give the answer to the
question of whether or not to give oral sulfonamides
in surgical cases.

Until then, there are too many
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factors which influence the prognosis of each individu
al case to evaluate any effect of the drug.
PRES.ENT STATUS
The usefulness of oral administration of the
sulfonamide drugs to prevent secondary infections in
eases of burns, wounds, and after surgery is as yet un
proveJI by controlled series.

TUBERCULOSIS
The spread of tuberculosis is so insidious
and inapparent, that control by a dr-µg that must be
given every day does not seem feasible.

The situation

would be different if one harmless dose eoul� prevent the infection from gaining
period of time.

a

roothald for a long

Experimentally, the sulfonamides could

conceivably be used to prevent tuberculosis, but clin
ically they could not.

During the early periods ot

sulfonamide investigations th& drug was tested with ev
ery disease known to man, first usually 1n laboratory
animals, and th�n if more or less successful, in man.
The work with tuberculosis never progressed past the
first stag&, even though some pretty optimistic re
ports were published.
In 1938, Rich and Follis ran a small series
of experiments on the preventive powers of sulfanil
amide against tuberculosis infect�ons in guinea pigs.
The results were:

(l) 100 mgm of the drug had no ef

fect in 400 gm pigs inoculated with a suspensi�n of
virulent human type tubercle bae1111J

{2) 200 mgm per

day caused a significant drop in the number of tubercles
in six animals as compared with that in six controls;
(3) 500 mgm per day �revented the appearance of palpable
•
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lymph nodes, and all apread of the organisme was con
siderably less, even though there was no complete pre
vention. of growth of the bacilli.

Greey, Campbell, and

Culley (1938) used somewhat different methods, but found
the same thing.

The lesion& in the spleens and livers

of the animals that had received prontylin powder be
fore injection with a suspension of virulent human tub
ercle bacilli were small and few in number in contrast
to the many prominent tuberoles in the control animals.
This difference was even more marked microscopically,
and but few acid-fast bacilli were found in the le
sions compared to those of the controls.
At the present time, it is doubtful if any
one uses any of the sulfonamides for the prqphylax1s
of tuberoulos:ts..

This is no doubt due to the fact that

the incidence of reaction from the least toxic of the
drug group is greater than the danger of infection, even
in individuals who associate with cases of the disease

every day, and the effectiven�as of sulfas against the
acid fast organism� is negligible.

PRESENT STATUS
The use of the sulfonamides in the prophylaxis
of human �ubereulosis is ineTreotual and impractical.

VIRUS DISEASF.s
Poliomyelitis - Influenza - Measles
The reports on the experimental work on the
prophylaxis of virus diseases in animals by the sul
fonamides have been consistantly pessimistic, but a
few clinical reports have seemed to show some favor
able effects, even though they are not mathematically
valid.

Thus, in 1937, Kelson experimented with Macaeus

rhesus monkeys which he inoculated intranasally with
fresh poliomyelitis virus cord suspensions.

Protected

monkeys received 50 co of l per cent saline solution
of sulfanilamide subcutaneously twice a day starting
three to four hours before the fiTst inoculation with
the virus.

In two small series, two monkeys survived,

one treated and one control animal.

There was no sig*

nifieant difference in time of the onset of paralysis,
the time of occurrence of complete paralysis of the
extremities, or in the day of c;leath between the two
groups.
Toomey and .Takacs (19�9) used sulfapyrldine
in Macacus rhesua monkeys which in these experiments
were inoeulated w�th 0.5 cc. of 1 per cent purified
polio vlrus suspension of Flexner•s M.V. strain.

Two

daya later, each of four of the animals received 0.5
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gm. sulfapyridine twice a day for seven to ten days
when massive paralyses appeared.

They concluded that

neither was this newer sulfonamide effeetf\n the pro
duction of experimental poliomyelitis in monkeys.
A report given at the proceedings of a staff meeting
of the Mayo Clinic (Rosenow 1939) showed

some

results

that might even indicate a contraindication to the
sulfonamides in this disease.

Using about the same

technique as above, there was little difference found
between the protected and unprotected monkeys in the
initial symptoms and paralysis.
symptoms

However, the initial

or mild encephalitis became more pronounced in

monkeys with sulfapyridine than in the controls.

This

was thought to be an additive neurotoxic effect.

In

the ffprotected" animals, the period of incubation was
shortened, the paralysis progressed more _rapidly, the
symptoms were more pronounced, death occurred earlier,
and the lesions of the spinal cord and brain were more
destructive and more.extensive than in the control an
imals.

These experiments seem to indicate that the

sulfonamides a.re contraindicated in the treatment of
poliomyelitis.

Coggeshall and Maier (1942) also de

cided that in experimental poliomyelitis in white mice,
all of the sulfonamides tested proved to be of no use
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in delaying.or preventing the disease, or even 1n re
ducing the mortality from the infection.
Rhett (1940) gave neoprontosil to four hun•
dred forty acutely 111 children du.r-ing an epidemic of
poliomyelitis in the dose of �bout one grain per pound
per day to test the prophylactic effect.
•

Of these,

only one developed paralysis, which was transient, de
veloping on the fifth day when the maintenance dose had
not been kept up.

The symptoms subsided when full

dosage was resumed and in three weeks, the paralytic
involvement had completely subsided.

In fourteen cases

of pre-paralytic poliomyelitis, neoprontosil was given
and only one developed paralysis.

Since this work does

not have a control series it cannot be accepted for
any proof of the validity of the beneficial prophylac
tic effect of the sulfonamides on poliomyelitis.
In work on the influenza virus in white mice,
Coggeshall and Maier 1942) the results of attempted
prophy1ax1s by the sulfonamides was likewise disappoint
ing.

The personnel of a Naval Laboratory research unit

in Berkeley, California (Krueger 1943) found that d:oses
of one milligram of sulfanilamide, sulfathiazole, sulfa
pyridine, and sulfad1a.z1ne given with an inoculation of
ten minimal lethal doses of a lung virua in a mouse
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and this repeated daily, failed to protect the develop
ment of the infection.
With this background of work, a curious fact
was observed by Painton (1944) in his large series of
Army oases (see discussion on meningoooccie infections).
In his study of 18,000 men r&ceiving p�ophylactic aul
fadiazine, five grams in four doses, he noted an un
expected drop in the incidence of a contagious virus
infection, measles, for a week.

This did not seem to

be due· to better weather conditions.
PRESENT STATUS
In view of the work on experimental animals,
the use of prophylactic sulfonamides in poliomyelitis
or virus influenza does not seem to be any benefit in
protecting exposed cases.

The prevention of measles

by the drugs 1s at present uncertain.

TOXIC REACTIONS
It was evident from the first that the sul
fonamide drugs were not without toxie reactions and that
caution must be exercised with their use.

Williams

(1957) found that nausea and vomiting occurred in some
cases of puerperal fever treated with prontos11, and
Colebrook (1937) warned of the danger of "acute hemo
lytic anemia" �rodueed by the drug.

Penington {1940 A)

found that nausea, dizziness, disorientation, mild in
toxication, mild acidosis, cyanosis, fever, malaise,
skin irritation and tinnitus were rather frequently ob
served with the use of sulfanilamide.

Another risk be

found (1940 B) was a depres_sion of leukocyte� in the
blood stream.
The frequeney of drug reactions with the pro
phylactio use of the sulfonamidos has been charted (see
(p-11)
Chart 2). Although no statistical analyses have been
made, it can be seen from the general trend that with
the present doses and newer drugs, the chance for a
toxic reaction is only about one in two thousand as
compared to about one in five to ten as reported only
five or six years ago.
The types of reactions may be divided into
(1) allergic and (2) general toxic.
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Although there is

75

no basis for this division, it will be used as a matter
of convenience in the following analysis.

Asthma, cutu,.

eous and conjunctival reactions will be considered "al
lergic", while gastrointestinal, nervous system, gen
ito-urinary and general symptoms will be discussed as
simply "toxic" manifestations.

The only exception to

this would be the mechanical effect on the kidneys by
excessive amounts of sulfonamides.
I

Allergic:

(See chart 3)

Asthma as a result of sulfon

amide ingestion is rare, but two eases were reported
by Randolph and Rawling { 1944).

Skin lesions usually

appear between the second and tenth day of therapy.
(Vilter 1944 ).

The sulfonamides usually produce a ten

der erythema nodosum, ·especially on the extensor sur
faces of the extremities and on the face, or they may
produce morbilliform localized or widespread erythema
tous rash whleh may become pustular.

A conjunctivitis

with •r_ythema and moderate edema may also oecur.
II

Gastrointestinal:

Nausea and vomiting

are i_nfrequent sequels to sul.fathiazole therapy, and
rare after aulfadiazine (Vilter 1944).

it usually oc

curs with the first dose of the drug. Hepatitis is
rare.
III

Nervous system:

asymmetrical (ibid).

Poly-neuritis is usually

The time of onset of the pain,
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paining, numbness, or tingling may be seven days or six
months.

Deler1um as a result of_ therapy is difficult

to ascertaih, since it is so often accompanied with
fever (ibid).
IV·- Skeletal system:

Poly-arthritis may occur

between the second and twelfth days (ibid).
V

Blood:

clinical symptoms:

A leukopenia may be mild with no
a thrombocytopenia has hemorrhagic

phenomena; hemolytic anemia has accompanying jaundice;

and agranulocytosis has dirty ulcerations in the mouth
and pharynx (Vilter 1944).

The big fear that agran�

ulocytosis will fol-low the rise of sulfa is exaggerated,
since by 1942, only 27 cases have been reported, 15 of
which were fatal.

All. these occurred between the second

and seventh week (Thomas 1942) of heavy therapeutic
doses.
VI

Genito-urinary system:

Toxic intrarenal

lesions without 111eehanical obstruction may be simple
tubular �egeneration, neurotic tubular degeneration or
glomerular changes, or a combination.
Polley, and Grill 1944}.

(Murphy, Kuzma,

These lesions have been studied

in animals by Endicott, Kornberg and Daft (1944).

The

s_igns that should be watched for are ( l} a.lbuminuria,
{2) oliguria, (3) anuria, {4) generalized edema, (5)
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sulfa orystals, red blood cells, casts and debris in
the urine (Murphy et all 1944).

Vilter (1944) suggests

that with sulfonamide therapy, daily cheeks sho uld be
made on the .fluid intake and output, and the red blood
cells in the urine.

Mechanical obstruction of the ur

inary system with sulfonamide crystals is rare with
small prophylaetio doses.

The deposits may be extran

epbrie or intranephric (Murphy, et al,. 1944).
VII

General SYl!lptoms:

Fever is a fairly

common complieation of sulfonamide ingestion, and oc
curs most frequently between the fifth and tenth days
of therapy.

It eommonly goes above 102 degrees -and

may be as high as 106 degrees with chills.
1944)

(Vilter

It is difficult to distinguish drugs and in

fection fevers, and an accurate analysis of oases can
not be made.
Since the purpose of this paper is to dis
cuss only toxic effects from the use o.f prophylactic
dosages of the sulfonamides, a chart has been d�awn
from the results of two large series

or

eases.

Vilter

{1944) reviewed 1936 cases in whieh therapeutic doses
of the drug had been given, and Lee (1944) gave 25,000
military personnel a single dose of� gm of sulfad1azin e
a daJ for five days.

All known sens1tiv& persons were
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excluded from the'test, and of course this lowered the
incidence of to�ic reactions.

The total_number of re

actions was 128 (.51 per cent), and of these, nine
{.36 per cent) were serious enough to require hospit
alization; four more (totaling .052 per cent) were ser
ious.

The types of reaction (Seet�t 3) were divided

into the (1) mild cutaneous (2) mild general (3) severe
general, and serious general.

The treatment that was

successful in all cases was intravenous dextrose and
epinephrine.

CHART 3
TU':&s OF TOXIC REACTIONS
Vilter (1944)
Therapeutie Doses
1,936 Cases
Per cent Reactions
I

II

Allergic

A. Asthma
B. Dermatitis
c. Conj�netivitis

Gastrointestinal
A. Anorexia
B. Nausea and Vomiting
c. Hepatitis

2
0.5
0.7
0.05

Nervous System
A. Polyneuritie
B. Delerium

0.3
0.15

IV

Skeletal System
Ae Polyarthritis

0.2

V

Blood
A. Leukopen1a

0.25

III

VI

VII

B. Thr.ombocytopenia
c. Hemolytic Anemia
D. Agranul!oc"ytosis

0.2
0.1

Genitourinary System
A. Toxic Nephritis
B. Mechanical
Obstruction

0.25

General
A. Fever

2.2

0.9

(continued on next page)
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CHART 3 (Cont)
Lee ( 1944)
Prophylactic Doses
25 # 000 �ases

.08% reactions
Dermatitis
Conjunctivitis .06% reactions
100 mild general reaetions--0.4%
i. nausea
2. diarrhea
3. vomiting
4. faintness

reactions--0.24%
1. mental haziness

6 severe general

2. chills

3.
4.
5.
6.

fever
edema
burning, itching
clouded sensoriam

3 serious general reactions-.012%
1. fever, arthritis, edema
2. malaise, collapse
3. dizziness, vertigo,
unconsciousness.
Comparison of the type of reactions of ther
apeutic and prophylactic doses of the sulfonamide based
on large series of cases.
PRESENT STATUS
Using the most effective prophylactic dose
(one gram per day), and the least toxic sulfonamide
(sulfadiazine), there may be expected an incidence of
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of 0.3 per cent to 0.6 per oent toxie reactions.

o.oa

About

per cent will have a dermatitis and 0.06 per cent

a conjunctivitis. About 0.4 per cent will have "mild
general" reactions, with nausea, diarrhea, vomiting, or
faintness.

About 0.024 per cent will have "severe gen-

eral" reactions, with mental haziness, chills, fever,

edema, bg.rn1ng, and itching.

About 0.012 per eent will

have "serious general" reactions with fever, arthritis,
edema, malaise, dizziness, vertigo, and collapse.
There should be no fatalities if the drug 1s
withdrawn immediately with toxic symptoms.

Intravenous

dextrose and epinephrine are efficacious in treatment.
ProJ)hylaotie sulfonamides should be given
only under constant supervision, with routine examin..
ation of the blood and urine.

Senior
Author

Year

Williams
Massell

1937
1937

Thomas
Coburn
Coburn
Thomas
Stowell

1939

Sako

1938

1939
1940

1941

1941
1941
Thomas
1942
1942
Hansen
1942
Kline
Kuttner
1943
Watson
1943
Chandler
1943
Messelof'f ·1943
1943
Arthur
1943
Lucchesi
1943
Strong
1944
Warren
1944
Dodge
Army Bull. 1944
l.944
l._944
Holbrook
1944
Coburn
1944
Hodges
1944
Keet
. 1944
Lee
1944
Painton
1944
Thomas

Daily
Intake

Drug
p

Jleriod

2.7 gm
?

p

s
s
s
s
s
s
s
s
s

3-5
1
2
2-3

-8 M

4.5
2.6

l-5

6

ST
SG

6

1 D
8 M

l-2

l

s

s

.6-l.5
1.2

S & ST

6

SD

s

SD
SD
SD
SD
SD
ST
SD

SD
SD

? -

8 M

1.2
4.5

ST
8
SD

wk

3 gm wk

1-a
½-1

8 M
l D
-

5 D
8 M

'l
.1..'...1
i
s--1

Reaotions

8
4
4
3

3
18

---

l D

5D
5 D

l�l

Chart 2

SD - s-ulf'adiazine

SG - sulf�gu.anidine
ST - sulfathiazole
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D

-4
0

78
1000
216
1000
18
25
253

12

3

1
2
2

2

34

11
3000
2

2
128
6

750
1500

- days

"-" -... months
several days
M

-

32

Summary of drug reactiona fr-Om the prophylactic use of
the sulfonamides. Seetext for discussion
Abbrevi�tiona:,
p - prontos�l or prontolyn
s - sulfanilamide

53

14
100
41
30
184

'9

46
215

l
l
2
5

Total
Patient

to
several months.

-

56
9000
181
600,000

-

40j-OOO

43,000
10,, 000
3000
25,000
18,000
250,000

Types of
Percent
Reactions Reactions
16
30
4
7
10
10

-

28
50
5

0
6

0.3
5

8

o.a

4

0.4

6

0.5
0.1
0.5
0.02
0.06
0.5
0.03
0.3 -·•

vomiting and eyanosis
macul•papular rash
two leukopenia, two fever and rash
vertigo - drug not stopped
"toxic effects"
"elasaieal symptoms"
none serious
one death from agranulocytos1s
stopped drug
nausea, fever, rash
rash, anorexia, three�pts changed drug
no blood, urine findings
fever, nausea; vomiting, derm•titis
rash
one withdrawn
anorexia, moderate decreas$ in bemoglobin
mil'd, granuloeytopepia, maoulopapules
n.egligible
cyanos1s and seleritis
none serious
insignifie.ant, drug continued
45 severe, no deaths after drug stopped with s�ptoms
dermal, no deaths
12 lost days, 33 mild
mostly evanescent rashes, .01% dange�ous
some moderately severe
one reaction with fourth dose
none serious
skin eruptions
mostly mild

PHYSIOLOGICAL EFFffl)TS OF PROPHYLACTIC SULFONAMIDES
That there are many possible toxic and phys�o

logical effects with.therapeut!c doses of the sulfon

am-ide drugs is admitted, and that problem has been dis
cussed previously.

This section is to discuss the

physiological effects of prophylactic doses of the drug
as obseryed chiefly by a group of investigators worldng
with military personnel.

Because of the widespread_ use

or

of sulfadiazine and aulfathiazo1� in the prevention

diseases listed in this paper, it has become important
to know the effects on the personnel involved.
question that should be answered is:

One big

Do small doses

or

sulfonamide adversely affect vision, muscle coordination,
endurance, or other p_hysiologjcal processes upon whioh
fighting efficiency depends?
It has been a po11cy of the A.AF to require

flying personnel to be grounded during sulfonamide ther"
apy and for six days thereafter.

The Navy rules that

aviators and airora£t crew members not be permitted to
take pa�t in flights until two days after the oral ad•

ministration of sulfa (Reynolds and Shaffer 1943).

An

e.xper�ent w.:ith rabbits {Lawson 1942) indio-ated that
heavy doses in,oreased the resistance of the animals to
low oxygen tension.

The animals were.found to te..lera.te
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about 3000 feet more after reeeiving the drug than be
fore, probably because of a retention of carbon dioxide.
Under the- �xperiment c.onditions set up, the increased
tolerance was definite and consistent, and it wa s not
though� to be due to the inhibition of carbonic an
hydrase.

When methemogl.obin was formed in these an

imals, the altitu4e tolerance was definitely lowered.
The experiment probably.has little to do with the sit
uation of fl_ying personnel.
Careful studies (Reynolds, Evans and Walsh

rta_lle�tl.°M,�

l943}Aen visual. eff1�1ene� before and after 4

gm

sulfa-

thiazole or sulf'adiazine given in twenty�!Ol:\P hours,
tests being run at eight and thirty-two hours a:fter the

last dose of drµg.

The conclusions were:

(1) There were no signifieant change• in

visual acu1t7 fo�lowi�g the adm1nist�at1on of either
qrug.
(2)

'?here was no definite alteration of

muscle balance a t· 20 ft. vision.

For near vision there

was a notable tendency towaTd iner�asing exophoria.
(3) One _h�l..f of those getting sulfath.iuole
were i"ound to have lessened power of.adduction; none
the other half had inpreaaed power.

There were no
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(4) Sulfiathiazole caused a transient re
duction in eff1e1ency of adduction of the ocular
muscles.
(5) One-half had disturbances in -efficiency
of convergenee.
(6) There were no consistent effects on acc-oinodation.
(7) One half those receiving sul.fath1-...ole
were less efficient in depth perception, but not sig
nificantly so.

Sulfadiazine eaused consistent marked

lessening of efficiency in space perceptiJ:>n and this

was persistent for 48 hours.
(8) Irregular enlargement of the blind spot
occurred� more noticeable with auli'adia�ine.
It has also been feared that ther, will re
sult such symptoms as impaired judgment from the use
of the sulfonamides and thus j�stifiable objection be
raised.

The dictums of the A.AF and NAF are based on

reacti-ons following sulfan11am14e (Reyn_Qlds and Shaf
fer 1943).

In one series {ibid) it was concluded that

sulfathiazole or aulfadiazine might be safely admin
istered up to 4

gm

daily to thoae;doing heavy manual

labor or exacting mental work.
In a more detailed survey ,(ibid), Ot�s
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tests of mental ability, vocational tests, cancellation
tests, and a pattern completion test all failed to show
any s�gnificant effect upon mental efficiency nor upon
hand to eye coordination by sulfadiazine or sulfathia
zole, considering the group as a whole.

Statistical

analysis of the data obtained shows considerable more
scatter about the mean values in sulfathiazole for most
of the test.

The greatest scatter resulted from notiee

ably poor performances by a few individuals within this

group.

There was reason to-believe that a few indiv

uals may have an idiosyncrasy toward sulfathiazole, re
sulting in decreased mental effioienoy and impaired co
ordination.

This idiosyncrasy was not seen with sulfa

diazine.
It is noteworthy that in the series'reported
by the Navy and the Army (viz. Kline and Ryan 1942 and
Arthur and Dermon 1943) the men receiving sulfa drugs
continued their daily work, and only the more serious
drug reactions required hospitalization.
PRESENT STATUS
In a fair percentage of cases there are small
eh�nges in visual, efficiency with th� daily ingestion
of one gram of sulfadiazine or sulfathiazole 1 the former
being less obnoxious.

With most persons this change· is-
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not great enou.gh to call -for a change in dail7 routine,
but in extremely technical positions sueh as -�iloting,
caution should be used in the ind.iseriminate use of
these drugs.
There are no tangible changes from prophylact1e
doses of sulfad1azfne or sulf'athiazole on mental e.t:
fieiency, heavy manual labor, or hand-eye coordination.

ACQUIRED SENSITIVITY
The literature ha s become flooded with re
ports in which patients "seemed" "apparently• to ac
quire a sensitivity to the sulfonamide ,drugs.

Frank

(1937) even reported two cases which apparently ac
quired heliosensitivity from ta1ting one of the drugs
over a long period of time.

Salvin (1937) remarked

about the similarity between a reaction to sulfanila
mide and a true allergic reaction.

One clinical fea-

ture that has been stressed is that the reaction with
a second dose e:f sulfa occurs much earlier than with
the first dose.

A patient was given large doses o:f

sul:fanilamide over a long period of time for

a severe

beta hemolytic streptococc1c pharyngitis (Gallagher
1939), and subsequently developed a typical drug fever
and a diffuse morbilliform _rash over the entire body.
Two years later,·when sulfanil8.Jl'lide was given again,
there was malaise, headache, chilliness and fever in
few hours, and in 36 hours there was a diffuse mor
billiform

rash.

This was o:ffered as presumptive evi

dence that a person can be sensitized to the sulfon
amides.
Other pessim1stie reports:
Bullowa ( 1940)

Davidson and

reported how· a patient- was apparently87
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sensitized to sulfapyridine and sulfamethylthiazole.
With the first administration there was no reaction,
but two days later sulfathiazole (5 gm) was given and
Later, 0.5

on the fourth day a temperature resulted.

gm of sulfamethythiazole ca.used scarlitiniform eruptions,
pruritis; fever, ehill;y sensations, and conjunetival
injection.
actions.

Sulfanilamide failed to elicit any toxie re-

Stiles (1941) cited four cases in which after

small doses of sulfatbiazole were discontinued, 0.5
gm

produced nervousness, chills, malaise, and fever.
Sams and Copeland (1941) presented a patient

who was apparently sensitized by local applications of
sulfathiazole powder, and who several weeks later de•
veloped dermatitis and a massive edema of the faoe and
ea.rs when given oral sulfathiazole.
The use of topical �ulfonamide applications
has been thought to be especially prone to produce a
sensitization •. Cohen Thomas and �alisch (1943) told
of two eases in which sulfathiazole ·ointment was ap
plied to large areas of varicose ec�ema.

Fever and a

general toxic rash promptly deve1oped which subsided
with the cessation of the drug.

Ingestion of small

amounts of sulfathiazole)roduced the rash.

Miller

(1942), Shaffer, et al (1943) and L1vingsgood and Pil-
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lsbury (1943) have commented upon the fact that if the
patient is sensitized (apparently, anyhow) by a topi
cal application of sulfa, oral medication will cause a
prompt exaceration of th� toxic erruption, worst at the
site of the application of the drug.

This was thought

to be significant in supporting the hypothesis of sen
sitization.

In some eases (ibid) a history of sensit

ivity to many substances are elicited, but in others it
is not {Salvin 1937).
The actual nature of sulfonamide reactions
is unknown (Nelson 1942) (Green, et al 1943).

Many

attempts have been made to find an allergic reaction.
Goodman and Levy (1937) found one case 1n which a "sug
gestively positive scratch reaction" developed and an
erythematous flare of the face and arms that developed
in another when 0.6 gm of drug were ingested.

They

thought this gave credence to the possibility of induced hypersensitivity.

Some investigators tried but

failed to elucidate an allergic mechanism of read.min
istration reactions (Mainzer 1938) (Loveman and Simon
1939), but Lyons and Balberor (1942) suggested that the
relative specifieity of the reaction pointed ·toward the
antigenic nature of the drug in spite of the fact that
sensitivity to any <lrug could not be demonstrated by

..
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scratch, patch or passive transfer studies.

They con

tended that the incidence of the rea-c·t1on is enhanced·
by an interval between the courses, in contrast to the
continuous administration of the drug.
Hoping to elucidate the faet that one course
of the dPug increases the chance of a reaction on the
second administration, Keith, Ross, and Thomson (1944)
made skin tests on patients before and after prophylac
tic sulfa was given.

Before the medication two out of

407 tests were positive, neither individual having ever
received a sulfonamide before.
into control groups.

Both of these were put

After medication there were no

positive reactions, but there were more "doubtfuls"
than before, but this was not thought significant be
cause there were reversible doubt£uls in three weeks.
The incidence of acquired sensitivity was reported by
these men (ibid) to be "very low" in the
Navy.

u.s. Army

and

As yet, there has been no study on the ef
fect of the mass prophylaxis of the military forces on
the sensitization of individuals to the sulfonamides.
A few individuals seem to manifest true allergic re
actions, and it has been shown (Davis 1942) that the
aulfonamides eould combine with plasma proteins, and
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perhaps -act as haptenes and in this way sensitize the
body specifically (Rich 1942).

Therefore, there might

be a ciroulat1ng antibody in the blood of an individual
receiving therapy (LESftrieh l.9441.

Leftwich used this

idea to work out a dermal teat that seemed to be ef
ficient about 95 per eent of the time.
The ordinary simple intolerance to sulfa should
not be conf'used with hype.rsensitivity, which is mani
fested by unusual., but characteristic reactions (Nelson 1942).

The "intol�rant" person shows only the us

ual toxie signs 1n a like situation.

Fever, dermatitis,

and conjunctivities are the not uncommon side effects
of sulfathiazole during its first administration.

These

can and do occur at any time during the course of ther
apy, whether it is the first or second administration.
The fact that eosinophllia is often found in sulfa
patients does not indicata hypersensitivity (Green,
et al, 1943).
The incidence of reactio�s with the read
ministration of the sulf'onamides of' course cannot be
determined from isolated case reports of euch alleged
occurences.

Control series are needed.

Lyons Alld Bal-

beror ( 1942), reported an incidence of 36 per cent ,re-·
actions following sul;.fathiazole read.ministration in
,
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the same individual.

This was given considerable at

tention (J.A.M.A. 1942) (Nelson 1942} and many cautious
practitioners began to only give sulfa as a last re
sort.

Another series (Rantz 1942) reported almost as

bad results, with a 25 per cent incidence of reactions
w�th the second dose.

Such studies, however, do not

reveal any dependable facts unless they are controlled.
One such investigation (Green, et al, �943) was me.de
at the Station Hospital, Camp Haan, California.

Ill

effects following sulfathiazole readministration were
observed, but not as frequently as 25 or 36 per cent.
Fifty-five cases were reviewed and it was found that
only 11 per cent experienced any type of side effect
during the second or subsequent courses of medication.
This 1s practically the same frequency and severity as
those seen following a single administration of this
drug.
Nelson (Leftwich 1944) found that the in

·Oidence of a febrile or cutaneous toxic reaction to
be 11.2 per cent during the first administration of
the sulfonamides, with approximately the same in
cidenoe (10.4 per cent of 133 patients) on the second
administration in those patients who showed no re
action with the first course or t herapy_.

In all, 964
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patients were studied.
The seriousness of the reaction seems to be
only in the minds of the pessimistic, and Coburn (1944)
concludes, "The collected findings indicated that a
small percen�age of persons have an idiosyncrasy to
sulfonamide compounds administered in therapeutic or
prophylactic doses, and that aulfadiazine prophylaxis
per se does not sensitize."
Holbrook (1944) considered the possibility of
individuals becoming sensitized to the drug on a mass
scale, which of course is an important problem when it
is remembered that ten to r1fteen million people in
the United States received a sulfonamide drug in 1941
alone (Long 1943).

He found that in repeated periods

of prophylaxis with 40,000 men that there was no in•
dication of a developing sensitivity.
PRESENT STATUS
The rate of toxic reactions with the second
administration of the sulfonamide drugs is mo greater
than that with the first administration.

The apparent

sensitisation by small doses in certain reported cases
has not been substantiated by laborat.ory studies or in

large controlled aeries.

PRODUCTION OF DRUG-RESISTANT BACTERIA
If the administTation of small amounts of
sulfonamidea suco�eds only in the developJ1utnt of strains
of bacteria not sensitive to the drugs, the benefit from
their prophylactic use is but relative.

Many··reperta of

cl!nical observations have been published _in which pneu
mocoeoi (Ross 1939) (Lowell, Strauss, and Finland 194·0)

(Auger 1941) (Frisch 1941) and streptoeooci (Hendry 1942)
(Wright, Cruikshank, and Gunn 1944) have been.'tho-ugtl.t· to

develop a resistance to the ehemotherapeutie agenta • . In

these cases, however, the amounts required to cause it
were quite large.

Ross (1939) reported the development of sulfa.

.

pyridine resistant pneumoooeci during the treatmen� of
a case of meningitis.

He used a slide-cell teehnie

which measured the sensitivity in terms of ability of
organisms to survive in a blood-saline mixture eonta1n1ng M & B 693.

The greatest difference in survival

shown by his "resistant" and "sensitive" straina amount
ed only to 0.6 per cent (i.e. there were no survivals
out of 850 pneumoeocci before treatment, and fi�e out of
950 after treatment.)

Such a small difference was th�ught

to be without aignifioance.
Lowell, Strauss and Finland (1940) round two
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cases of pneumonia, and one of meningitis from which
sensitive organisms were isolated prior to treatment
and moderately -resistant organisms were encountered
afterwards.

Sultapyridine resistance of pneumoooeci

(Auger 1941) following sulfapyridine therapy in in

fants and children has been apparently demonstrated by
laboratory tests.

Frisch (1941) reported seven cases of

sulf'a-resistant organisms that purportedly developed
during tr�atxnent, but only two seemed to be thus.

The

other five showed almost as much resistance before as
after.
Hendry ( 1942) has demonstrated the develop-

ment of drug resistance by a Group A streptoeocous.

In

another investigation (�right, Cruikshank and Gunn

1944), streptocoec1e cross-infeetions occurred despite

sulfonamide given to a majority of patients on hos
pital wards_.

The strains that were spread were found·

by in vitro tests to be sulfa-resistant •.
The first controlled series to appear in the

literature was performed by Julianelle and Siegel (1943J.
Thirty children received 1 to 2

gm of aulfadiazine a

day for four months, and thirty children were observed
as controls.

The drug only caused mild transient symp

toms of toxicity t.o appear.

Bo.th groups had a similar
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number of colds and minor respiratory infections, with
no signifieant difference in the average duration of
illness.

The total number ef organisms recovered from

the sulfadiazine group was not less than in the con
trols.

Some organisms were affected, but others, and

especially the gram-negative d1plococc1>were strik1ng1y
reduced.

After one month of treatment, however, these

organisms again increased ., and sulfadiazine res.istant
strains were encountered.
among pneumococci.

S1nr1lar ch9:nges were noted

In the control group, many types of

pneumoeoec1 were encountered continuously throughout
the study.

In the .sulfadiazine group, the same mul

tiplicity of types was noted at first, but within a
short time two types dominated.
I

Tests showed that these

two types "had become" sulfadiazine resistant, and

shortly thereafter these same two types of pneumococc1
had spread into the throats of the control group of
children, who were housed in the same cottage.

The

one saving feature was that these strains were evident
ly avirulent.
Kuttner (1945) found that fourteen out of
eighty children reoeiving prophylactic sulfa became
carriers of strept-0eccc1.
The most complete study has been done by

Hamburger, Schmidt, Sesler, Ruegsegger and Grupen
(1943) who used a refined technique to test the re
sistance to sulfa of pneumoeocci before and after a
course of therapy had been °given.

Three hundred forty

sev�n cultures of pneumocoec1 were obta:tned from 168
patients before treatment, and no extre�ely sensitive

strains were found.

There were variations in sensi

tivity, but these did not correspond to the clinical
response to sulfa.

Seventy-two patients were studied

after a course of therapy over a period of at least
three days or for a total of 14 gm of sulfa.

Results:

Four cases showed a definite increase in resistance
of the pneumocoeei; there was no change in sixty; eight
cases varied, not in relation to therapy; and two.even
became more sensitive.

In three cases of prolonged

treatment (14 to 55 days) there was definite evidence
of sulfa-resistant strains.
cluded:

These investigators con

(1) Sulfa-resistant strains are rare before

treatment; (2) Sulfa-resistant strains may be acquired

under sulfa therapy; (3) The danger of this is not great

with brief treatment.

Coburn (1944) has offered evidence that

fastness to sulfadiazine was apparently not initiated
during the first four months of a prophylactic program
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among 43,000 military personnel:
"l. There was no increase in the prevalenee
of any serologie type or hemolytic s treptoooeous. 1n
the gI'ou.ps on prol)hylaxis.
"2. There was no inorease in the proportio.n
-of hemolytic streptococci in the throat fl()ra.of in�
d1v1duals throughout the period of prophylaxis.•3. There was no increase in streptocoo·o1c
morbidity tbroughout the period of prophylax1a.
•4. The�e was no diff1culty in o�taining a
satisfactory therapeutic erfeet from sulfadiazlne in
individuals who contracted streptoooccic inf.eet·iona
while receiving prophylaxis."

PRESENT STATUS
In some cases, sul�a-resistant bacteria have
been found in the tnroats of patients after small dosee
of prophylactic sulfonamides.

The danger is iner.ased

with lo� and intensive medication.

In othe� instanoes,

there seems to be no foundation tor the fear that soon
all bacteria will become sulfa-fast •

..

PROPHYLACTIC USE OF THE SALICYLATBS IN RHEUMATIC FEVER
As mentioned 1n a previous discussion, there
has been noted a clinical relation between hemolytic
streptococcal infections and rheumatic fever attacks
(Coburn 1944) (Thomas 1944).

There is usually a lag

of time after the bacterial infection until the rheu
matie attack begins.

Another interesting observation

that has been mentioned (Coburn 1942) (Schlesinger
1930) is that elinically a rheumatic fever attack re
sembles in many ways serum sickness, and it has there
�ore been postulated (Coburn 1942) that during the usual
period between a streptococcal upper respiratory in

fection and the rheumatic attack, immunologic changes
take place, with a decrease in the serum complement,
suggesting an antigen-antibody reaction.

During the

rheumati-0 attack, circulating preeipitins appear.

The

third piece of information which fits in is that the
salicylate drugs have usually been effective in pre
venting the arthritis of serum sickness and in patients
so treated the production of precipitins against horse
ij�rum was inhibited (Deriok, Hitchcock, and Swift 1927}.
With this in mind, ssveral series of experiments have
been carried out.

.

- .

Leech (1930) was one of the earli�r investi99
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gators.

He divided a group with inaotive rheumatic

heart lesions or with potential heart disease, into
two equal parts, and gave each patient in the first part
1.3 gm of aspirin daily, the second part being used as
a control.

He reported that of 67 patients receiving

aspirin, four had recurrences of chorea, but three of
these had only taken the medicine spasmodically.

The-re

were no recurrences of.acute rheumatic endocarditis or
periearditis.

In the control group, there were nine

recurrences of chorea, one with arthritis.

Six children •

had arthrit�s that needed aspirin but these were not
classified as recurrences.

On the average, there was

a little better weight gain in the aspirin patients, if
those with recurrences were not counted.

Fifteen chil

dren in the aspirin group and nine in the control gro�p
showed slower heart rates, but three in each group showed
an increased heart rate.

There was no great difference

in the deve1opment or disappearance of murmers 1 but
speculation was aroused as to the reason for the moder
ate preponderance of diminutions and disappearances of
cardie murmers among the patients with the salieylate.
There was no evidence that the drug affected the slowly
progressive initial stenosis, and the series was too
small to notice any possible effect in preventing en-
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dooarditis as a sequel to chorea or other manifestation.
However, the noted improvement in general body c01nfort
seemed to bring about an inerease in weight and in gen
eral better signs of improvement, and leas chorea.
Schlesinger {1930) gave aspirin to sixteen
children with acute tonsillitis, a condition usually
followed by serious rheumatic relapses in these sus
ceptible patients.
to age:

The daily dose was varied according

5 to 8 yrs.--.5

14 yrs.--0.6 to 0.8 gm.

gm; 9 to 14 yrs.--.6 gm; over

The aspirin was started at the

beginning of tonsillitis and continued for one month.
No serious rheumatic fever occurred in these cases, al
though clinically and bacterially the tonsils remained
In two oases, a fever developed ten to fif

the same.

teen days after therapy was begun, but without renewed
earditis.

The amount of aspirin given by this in

vestigator i"s less than by others, and since he ran
no control series his work cannot be evaluated.
Sheldon (1931) reported a controlled series,
but it is too small and inconclusive.

Seven rheumatic

children were given aspirin as soon as an initial fever
and sore throat appeared.

In three patients,.tspirin

seemed to modify the rheumatic relapse, each receiving

o.s

gm D.I.E. for six weeks, 0.6

and 0.6

gm

T.E.R. D.C.E.

gm

.

T.E.R. for 28 days,

for 24 hours.

The symptoms
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appeared after the aspirin was stopped in all cases.
One showed aorta aortie valve e-0mplioations, one sub
cutaneous nodules, and one rheumatic per1oard1t1s which
proved fatal.

In a fourth case, the rheumatic peri

carditis developed simultaneously with the tonsilliti�,

thus not giving the aspirin a ehance.

Three of the "as

p1rinated" children remained free from relapse after the
initial fever, however, hine children received no aspir
in and h�d no relapses. This report was rather dis-·
couraging.
Perry (1933) attempted a larger study and
f'ormed two similar groups of children with potential
heart disease.

Forty-one children received

o.s

gm

three times a day for a year, and 106 children were ob•
served as controls. A check-up was made every three or
f'our weeks as to symptoms, physical signs, a_nd weight.
Relapses, i.e. chorea, arthritis, or carditis, were
observed in 12.l per cent of the aspirin cases, and in
17.9 per cent of the controls.

Perry doubted·if this

difference was significant because those patients-who
were conscientious enough to take aspirin regularly were
in general better taken care of'.

.The treatment was

voluntary and often was· discontinued because the child
seemed well, or there was no impr�vement, or the child
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was neglected. Besides, the administration of the sal�
icylate did not_prevent re�apses.

The abnormal physical

signs in the heart decreased or disappeared in M per
cent of aspirin eases; and in 24.5 per cent o.f controls.
Howev�r, 12.1 per cent of the aspirin eases increased in
number of physical signs as compared to the 8.4 per cent
of the untreated.
The status of the aspirin method in 1937 must
not have been too go.od, for Massell ( 193'7) in his con

trolled experiments with the prophylaxis of rheumatic

.fever with prontylin used aspirin in his control series.
Although two of six patients developed rheumatic re
crudescences 1n each group, the investigator noted that
those re�eiving aspirin were more comfortable.
Schlesing�r (1938) reported a £air sized
series in which aspirin therapy given from the onset
of a throat infection lessened the .frequency of rheu
matic recurrences and in the event of a relapse recovery
was the rule.

In the treated group� there were 21 re

coveries with six deaths, and in the controls there were

13 recoveries and eleven deatha.
The most recent report has come from Coburn
(1942) whose figures may be analyzed and show the favor
able influence of sodium sal1oylate on rheumatic fever

."
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patients.

A group of these patients were kept under ob

servation, and at the onset of a pharyngitis each was
given 4 to 6

gm

of sodium salioylate daily for the next

four weeks, and continued longer if hemolytic strep�
tococci were found in the throat.

Of the 47 patients

treated this way, only one developed a clinical man
ifestation of rheumatic fever, and there was some ques
tion as to whether the drug had been taken, for the
symptoms disappeared when the drug was started in the
hospital.

Fifteen of the patients had a brief asymptom

atic rise in the blood cell sedimentation rate after
the aspirin was stopped.

The untreated controls had 57

rheumatic fever attacks in 139 cases of pharyngitis.
This difference 1s statis.tically overwhelming.
Coburn considered whether or not the salicylates
merely masked symptoms, and to eliminate the possibil
ity, the drug was stopped after four weeks, at a time
when rheumatic activity would be expected to manifest
itselt', but it did not.

There was no observed mod

ification of the antistreptolysin response by the aspir
in.

The investigator is a proponent of the theory that

salicylates prevent an ant1gen-antipody precipitation.
This action is 1xµ'luenoed by the concentration of sal
icylate ;.in the �ystem increasing with concentration,
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and the proportion of antibody to antigen decreasing
with an excess of antibody and being most marked in

the equivalence zone.

The mechanism ror interference

of immune precipitation by salicylate in vitro appears
to have its action on the antibody.
PRESENT STATUS
Rheumatic fever recrudescences may be pre
vented if every potential hemolytic streptocooc1c in
fection is recognized and then the patient given four
to six grams of aspirin daily for four weeks.

This

should be continued longer if the organisms are still
found in the throat.

PROPHYLACTIC USE OF BAYER 205 IN TRYPANOSOMIASIS
During a search for a drug which would cure
African Sleeping Sickness, Haendel and Joetter (1920),
German workers, diseovered that a new compound "Bayer
205" had an extraordinarily high trypanocidal aetion.
Besides promptly euring established cases, it exerted a
remarkable prophyiaotic action.

Doses of one mgm in

mice protected· against infections fourteen days later,
and equally good results were obtained with infected
rats, guinea pigs, and rabbits.

Other workers (Mayer

and Zeiss, 1920} confirmed the fact that this drug
,rovided an unfailing remedy at the height of infection
in the case of T. brucei, T. equiperdum, T. equinum,
T. gambiense, and T. rhodiense.

In prophylactic ex

periments, animals treated with larger doses of Bayer
205 were afforded protection against infection for some
months.

This prolonged aetion was thought to be due to

the fact that the remedy remained in the body for months
in an active form.
The chemieal nature of this efficacious drug
was kept a secret by the German investigators, ·because
of the politieal' situation.

The experiments were car

ried to Northern Rhodesia by Kleine and Fischer (1922)
where they used monkeys and infected tsetse flies.
106

The
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oral administration of the Bayer grug was found un
satisfactory and abandoned.

These investigators found

that 0.15 gm of. the compound protected a monkey for two
months against the bites of tsetse flies proved to be
infective with T. rhodiense or T. •brue-ei.

'!'hey concluded

from their series of experiments that the effect of 205
varies with the virulence of the trypanosome and the
species of the animal used.

In 1924, Lange and Kersten

found that they could protect miee for 47 days with l
mgm of Bayer 205.
With this beginning, other workers began to
find out what the effect of -this d:;ru_g -would be in pre
venting human trypanosomasis.

During the early twenties,

there was a lot of work done on the preparation of a
vaccine :for trypanosomiasis.

Kligler e.nd Weitzman ( 1926)

noted the prote-e-t-fug power of BQ.ye_r 205 in attempting to
immunize against trypanoaome infection with injection

of the d&ad or attenuated parasites.

As one method of

killing the organisms, the drug was used, and instead of
becoming hypersensitive as uaual1y happened, these anim
als manifested an increased resistance which in some
cases warded off· an 1nf'&ot-1on.

This acquired resistance

was not attributed to the protective aet1on of the drug,
because the same dose of the

dru�,

without the dead t�T-
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panosomes had little or only mild protective action.
This fit in with the observed clinical fact that ani

mals cured of Trypanosomiasis with Bayer 205 had longer
period of resistance than those only receiving the drug
prophylaotical_ly.

By that time, the chemical nature Qf "Bayer
205" was more completely known and it received seve.ral
names, among whieh were "g�rmanin", "suramin n , "mor
anyl", and

11

309 Fourneau".

It was found eventually to

be a sodium salt of the symmetrical urea of meta
amidobenzoyl-meta-amino-paramethylbenzoyl-levanaphthy_-
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lanimo-4,6,8,-tr1sulfonic acid.

By trial and error, it

was found to be more effective, and less toxie than other
. substances that were used as trypanocidal ag�nts.
Vanden Branden (1924.) was the l'irst of workers
who went to various parts of Africa to test the useful
ness of Bayer 205 in controlling African Sleeping Sick
ness among native population.

His first experiments

consisted of 1nooul�ting a section of a native pop
ulation living in an area known to be infected with T.
gambiense with the drug, another section of this popu
lation being left untreated to serve as controls.

He

concluded as a result of this aeries that the protection
conf'erred by a single dose of 205 (1 gm) lasted in man
for some nineteen months.

He also studied two villages

of Biza and discovered seventeen cases of sleeping sick
ness.

These cases were actively treated, and the �ealthy

1ndiv1duals were given two prophylactio doses of 205 ac
cording to the following scale, two to three weeks apart:
Adults--�-----1.
Young people•- .5
Childr�n------ .25
Sucklings-----0.l

gm
gm
gm
gm

Pre-existing cases were ruled out when each
individual received two examinations six months apart
(January and June, 1925) and then after the injections,
the- -examinations were continued every six months f�r
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two years.

Three cases were found during the next year,

oruy one of which had received the 205. There was rea
son to believe that this one was really infected when
he had the injections.

The investigator bel;eved he was

justified in inferring that the drop in infections could
be attributed to the prophylactic injections of Bayer
205.
A siightly different mode of study was attempted
by Fourche and Ricklin (1928). who set about to determine
if the Bayer drug could prevent individual.a from getting .
sl.e.eping sickness in heavily infected areas in Africa.
In certain villages, all healthy natives were injected
with 205 {one gram for adults) and comparisons were made
with villages in which only the infected were treated.
Since the population was in process of a turn-over, it
was dif�icult to make a complete check, but blood studies
showed a significant in�luenee of the prophylaxis.
.I

The

initial incidence ranged from five to twenty per cent,
which dropped down to one per cent even when only the
infected received active treatment.

However, when al

most all the hea�thy inhabitants received two grams of
205, the incidence was zero in seven months, and 0.22

per cent 1n ten months, and when one gram was given,
0.54 per cent in ten months.

These conclusions were
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reached from the results of blood studies on 1 1 681
invidivuals receiving Bayer 205.

This investigator is

the first to mention the toxio effects of the drug, but
says only that there were very few reaetiona, with one
death from cardiac syncope.
There have been several incomplete and 1n
oonslus1ve data., but nevertheless with "conclusive" re

sults.

One of these (De. Brauwere and Lisfranc 1931)

consisted cf experiments in an endemic area of sleeping
sickness with an incidence of twelve per cent.

There

seemed to be a reduction of infection when Bayer 205
and trypsonarsyl meuriee were given prophylaetically.
The investigators found that the injections should be
given every six months, with 205 ae the·best of the
two.
After all these promising experiments had been
reported, it came time for some pessimistie results,
and to be sure they did come.

De Marqueissac (1932)

very carefully coniucted a series t� test the tru� pro
phylactic value of Bayer 205 in three villages of Lama
Tessi.

The incidence of sleeping sickness before the

experiment ranged from 3 per cent to 9 per cent, the
criterion of infection being two blood and one gland
juice examination.

Two groups, as nearly identical as
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possible were formed, the first receiving prophylaxis of
.02 gm/xilo of 205 and the other serving as controls.
The next exam was made between 82 to 123 days later and
the results were disappointing.

Of 250 of those who

received the drug, twenty-six were found positive, and
of 257 controls, twenty-one were found infected.

This

investigation concluded that more careful consideration
of previous experiments should be made.
Finally some investigators who could write
English started reporting their results.· Corson (1934)
repeated some of the earlier experiments with sma·11er

animals and their resistance to trypanosomias1s trans
mitted by tsetse flies.

He found that a dose of .015

gram of Bayer 205 per kilogram of body weight did not
pr�tect white rats against T. rhodiense for 21 days,
and 0.03 grams per kilogram did not protect for 40 days.
He brings up a new observation, "The chief diffieulty
seems to be the question whether the �rug might cause
such alteration of the virulence of the trypanosomes as
to make the diagnosis difficult."
Several drugs closely related to Bayer 205
were being tried {Browning and Gulbransen

1934) and

many were found to have very short :prophylactic ef
fects.

Therefore, there was good evidence that the
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prophylactic action of 205 was due chiefly to its·pro
longed presence in the blood.

The action of the basic

drug is prolonged by adding benzoylamino group.
The f.inal answer to the ef.fioacy of Bayer
205 in the. prophylaxis of trypanosomiasis was given by
Duke, an English investigator, who conducted extremely
well controlled experiments in Uganda, first with mon
keys and then with natives.

He endeavored to seek out

every possible aouree of error and was meticulous al
most to a painful degree.

He captured wild tsetse f-lies

that were infected with T, bruce1 on Damba Island on
Lake Victoria.

A healthy monkey received two doses of

205 intravenously about nine weeks, and then two months
later it was fed upon heavily by the infected flies.
The blood remained free from the parasite, being ex
amined daily with thick smears.

The animal was bitten

with tsetse flies a month later and in two weeks the
try-pansomes were in the peripheral blood.
later it died.

Two weeks

All the flies were known to be infected

because they had proved inf'ectious to clean monkeys.
Therefore the animal had been kept from a normally,
rapidly pathogenic trypansome infection for 69 days
after the last injection of Bayer 205.
In his preliminary investigations with human
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beings, Duke (1934) used two groups of native volunteers
The tirst consisted of four men who had re

in Uganda.

cently been exper,mentally inf'ected with T. rhodiense
and then treated with Bayer 205.

Each man received six

grams in one gram doses intravenously at a few days in
tervals.

The second group was three virgin volunteers

eaoh of whom reeeived one intravenous dose of one gram.
In every instance, exposure to infection was by the bite
of a tsetse known to be infective to man, seven clean
volunteers being used as controls.

The period of im

munity for the first group lasted from 105-190 days, and
the second for at least 108-113 dayB.

Two (one of each

group) were.re-infected.

As a result of the first observations, he sets
forth two hypothesis:

(1) the degree of protection might

be proportional to the quantity of Bayer 205 used; (2}
the susceptibility of the body varies with the pro

tection eon.ferred by 205, thus signifying that an ani
mal's naturai resistance helps the �rug stave oft the
trypanosome.

The evidence presented suggested that the

maximum immunity is obtained from the trequently re
peated destruction of living trypanosomes in an organ
ism initially protected with Bayer 205.
To illustrate that the control measures used
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in this investigation w�re extremely rigid and detailed
the following is cited (Duke 1936):

First, the infec

tivity of the tsetse fly must be proven, and when the
syringe is used it must have a known infect1v1ty.

(l)

the variation in natural immunity among the natives was
a fac-tor, as were (2) the characters of different strains
of trypansome, and (3)-the immunizing effect (so far
quite unknown) of repeated small inoculations of living
trypanQsomes into an individual still under the pro
tection of Bayer 205, (4) the rate of absorption, and
(5) the elimination of the drug in the individual.

These

are all variables and only rough indications, not ac
curate scientific conclusions can be drawn.
in conclusion (ibid):

Duke says

"Indeed the more one studies the

trypanosomes of the bru¢e1 group in relation to man
himself the more apparent becomes our ignoranee of his
true place in their economy in nature. 0
At any rate, here are the results of the experiments he performed.

Of nine volunteers who re

ceived a single dose (one gram), four were infected by
the first ex.posure in 75-105 days.
protected f'or 97-327 days.

The other f'ive were

In five individuals who re

ceived a single dose of two grams, protection was in
duced for 128-180 days against T. rhodiense and T. gam-
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biense.

Four received protection for 164-206 days by

two one gram doses twenty-one days apart.

When inf'ection

did occur it did so in a normal manner, however there
were three or possibly five cases of delayed or "cryp
tic" infection.

The conditions for the development of

this latent and potentially dangerous type of infection
are dependent on the virulence of the trypanosome and
the resistance of the individual.

The general well

being of the individual is positively a factor, but the
pertinent question h�re is whether Bayer 205 predisposes
to "cryptic" infections, and if it does, does this con
stitute a vital objection to the use of the drug as a
prophylactic.

Duke (ibid) does not think so, because

these cases are amenable to treatment and they also
occur where no 205 has been used.

He concludes that

when protection is needed for some definite and limited
undertaking, Bkyer 205 should certainly be employed,
the dose being repeated in three months.
For the pr�tection of an indigenous population
of a sleeping sickness area, Bayer 205 may be employed
under careful supervision and with intelligent co
operation of the population itself with good results.
In areas where the disease proceeds unchecked by ciear
ing and other local control measures, then the drug can
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be valuable in giving eaoh inoculated individual pro
tection for two months or longer.

Only a few will show

cryptic infections, i.e., the patient showing no ap

parent symptOms for two months and possibly longer.

This may gradually generate typical symptoms or it may
become merged into a subsequent infection superimposed
and running a normal course.

This may arise without

Bayer 205, however.

In planning a program for trypanosome control,
it should be remembered that comparatively few infected
flies spread the disease and man acts as a reservoir..

The natives are i�arning that cooi,eration is best in
the long Ttin, and they volunteer, for exper1ments.

In 1938, Van Roof and Peel {1938) carried on

more investigations with Bayer 205 and Trypanosomes.
T-hey found that the resistance of T. gambiense to th&
drug ls of an unstable eharacter; it progressively de
creases on mechanical passages through mammals of the
same speeies, decreasing more rapidly still on mechan
ical passage� through mammals of different species and

even completel7 disappearing on eyclieal transm�ssion
through Gloasina palpalis.
-They worked in the Belgian Oongo (Van Hoot

and- Pe�l 1940), and repeated the exper1ments with
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guinea pigs, but varied the method in that they mixed
the Bayer drug in the feeding of the animals.

In this

way, 0,015 to 0.05 gram per kilogram per day was in
jected.

A dose of 0.025

gm

protected a guinea pig for

at least 58 days and for an average of 900 days.

The

question whether feeding the infective tsetse on guinea
pigs which had received Bayer 205 in any way affected
the infection in the fly was also studied.

In no case

did subsequent dissection of the individual tsetse give

any evidence that the infection in the gut or glands
had been influenced.

However, further observations

showed that there was a decreased ability of the flies

to infect

the animals after they had fed on some which

had received 205.

Ten out of eleven guinea pigs bitten

before the fly had fed on an animal. which had received
Bayer 205 became infected, while only fourteen out of
nineteen bitten after the feeding became infected.
Their results (ibid) obtained on guinea pigs
which had been given a prophylactic dose of Bayer 205
and subsequently subjected to the bites of infected
Glossint failed to give any definite support te Duke's
hypothesis that the liberation of antigen from trypan
osomes d-est-royed by the drug provoked the formation of
immune bodies, thereby contributing to the immunity
produced by the drug itself'.

119

In attempting to destroy the human reservoir
of trypanosomiasis in a limited area (ibid) for a period
sufficiently 1ong for the development of a clean stock
of tsetse, several reasons for failure arise.

First,

the duration of protection was shorter than the life of
the fly, second the parasit& was introduced from sur
rounding districts and perhaps from animals, especially
pigs, and third, probably certain natives escaped the
prophylactic dose.

However, one ot the results of mas

sive prophylactic injections (0.025 gram per kilogram
Gayer 205) in an endemic area is that the appearance of
the endemic seems to have ehanged; among the cases, the
proportion of those in the advanced stage is increased.
Massive prophylaxis as outlined in this paper 1s sug•
gested to curb trypanosomiasis.

PRF.SENT STATUS

An individual may obtain increased resistance

to trypanosome infections for a period of about three
months from one gram of Bayer 205 given intravenously.
Because of the animal reservoir it 1s not feasible to
eradioate the disease from an infected area by mass
prophylaxis.

SUPPRESSION OF MAI.AR.IA BY DRUG PROPHYLAXIS
The history of the use of drugs in the con
trol of malaria may be found in any good treatise
the disease, bY.t it will not be repeated here�

of

A few

of the more recent reports on the use of quinine, ata
brine, and pl.asmochen will be reviewed, and then the

A�t

official opinion o� theAmedica1 department will be reviewed in detail # tor in it is found the "present status"
of the control of malaria by drug prophylaxis.
During the Ethiopian campaign, a half million
Italian soldiers were given 0.6 gm of quinine bihydro
chloride or sulfate, and throughout the war there were
but 1241 hospital admissions for primary malaria and
1093 tor relapses (Castellani 1939).

This low incidence

was attributed to the rigid enforcement of the medi
cation.

Cassini (1939), �ter three years of study of

malaria prophylaxis and thera�y in Sardinia, concluded
that atabrine p�ophylax1s, especially in epidemic per
iods, and prompt treatment of all febrile attacks will
reduce malaria symptoms, enlarged spleen rates and para
site incidence rates, and effect a marked improvement 1n
the health of a population, but it eann.ot eradioate
malaria.
In another aeries (Teichler 1939), five hun-
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dred natives of East Africa in a highly malarial dis
trict were given atabrine �or three daya--0.l gm three
times daily.

On inspection of the persons involved a

week later, it was found that ten complained of .fever,
four of headache, one of giddiness and one of weakness.
This investigator felt that short c-0urses of atabrine
can maintain health of a labor force.
A controlled series was conducted in Jugoslavia
(Kostic and Antic 1939) in an endemic malaria region
among 240 prisoners and warders. Eighty-six untreated
� men were observed while 154 received 0.4

gm

of atabrine

each week. At the beginning of the experiment, there was
a ?.5 per cent incidence of parasites in the blood in
six months. This fell to 0.8 per cent in the treated,
and rose to 46.7 per cent in four months.

There were

.no 111 effects from the drugs, and all continued to
work.
-In twelve months of· study on the drug contro1
among six Chagres River villages (Clark, Komp and Job
bins 1941), comparisons were made between the effect
of quinine-plasmochen and atabrine-plasmoehen protection.
Quinine sulfate, 1 gm each day, or atabrine tablets ot
0.1 gm three times daily were given for five days, and
then in both series plaamochen, 0.01 gm twioe a day for

122

five days, was administ�t�ed.

The cumulative parasite

rate over a period of twelve months was 55.5 per cent

for the group getting the atabrine and 57.3 per cent for
the quinine.

The relative incidence of new in:fections

and relapses was a debated question.

Three facts sup

ported the opinion of these workers that most of the
positive cases of malaria were due to relapse rather
than new infections:

(1) the infant rate for the year

for initial infection was 2.5 per cent; (2) during the
year, the parasite rate in the children and in adults
was almost equal in the drug controlled towns, while in
uncontrolled rural villages in endemic centers the chJl
dren 1 s rate was, usuall7; almost double that of the
adults; (3) most of the positive blood films were ob
tained from the same individuals living with the same
family and sleeping in the same house, with an infection
that was not eradicated.

Talbot (1943) in a review of

reports also concluded that there may

be sub-clinical

infections of malaria in drug protected pe rsons.

He

prefers a routine examination of blood smears of all
exposed �ases with vigorous treatment of those found
infected to the use of drug prophylaxis.
The official opinion of the

u.s. Army

Med

ical Department (Editorial 1944C) has been expressed
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concerning the suppression of malaria by the prophylac
tic use of drugs.

Quinine and atabrine, the most com

monly used agents were found to be equally effieaoious
in suppressing the development of symptoms, but neither
drug would prevent mosquito-borne infection.

Because

of the extension of combat activities in highly malar
ious areas, it has become necessary that large numbers
of troops receive drug suppressive treatment.

Follow

ing the capture PY Japan of the principle sou.rees of
quinine, atabrine has been almost exclusively the drug
employed by the army.

The recommended method is to

give O.l gram atabrine once daily at the evening meal
six days a week (0.6 gm) with an alternative method
giving 0.05 gram atabrine once daily at the evening meal
six days each week and 0.1 gram on the seventh day (0.04
gram per week).
The office of the Surgeon General (ibid)
thought the following sentence significant enough to
ital icize: · "�t should be emphasized that drug suppres
sive -treatment is an emergency procedure which should
be employed only when troops must accomplish a mission
1n an area where there is substantial risk from malaria
and where protection control measures�are not possible.
When troops return to san1tated areas suppressive treat-
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ment should be discontinued as soon as feasible."
Once the decision to give drug prophylaxis to

a number of individuals, soldiers or civilians, has been
made, the time to start the suppressive treatment must
be settled.

Since experimental studies have proved that

the �axitpwp plasma concentration of atabrine is not at
tained until a.fter three to six weeks of medication, it
would seem best to start the drug several weeks in ad
vance of exposure (ibid).

However, it has been found

that in the majo�ity of cases that treatment in advance

of exposure is not necessary, because a protective level
is apparently reached within the incubation period of
the disease, at least when a dosage of 0.6 gram per
week is followed. For troops g__oing into combat, early
suppressive treatment may be started early (l) to dis
cipline officers and men in the routine of taking ata

brine, (2) to have the occasional disagreeable reactions

that accompany the first few doses of the drug over

with, and (3) to establish a blood lev�l of atabrine
quickly, which might be difficult to de once the troops
enter the territory.
The army has carefully considered the toxicity
of atabrine, but up to February 1944 no ill effects
-whatever had been noted in large groups of men who took
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the drug continuously for pertods longer than a year
(ibid).

No path�logioal ehanges have been discovered.

It has been frequently observed that the first few doses
of atabrine may be accompanied with nausea, abdominal

cramps, an occasional headache, vomiting and diarrhea.

These symptoms may be prevented in most cases by giving
sodium bicarbonate or sweetened drinks with the drug.

They almost invariably soon disappear_and are-never
serious even if the drug is continued. True intoler
anee for atabrine is rare.
There is no eontraindieatiom of atabrine in
aviation, with no detectable adverse effects on the
physiologieal reactions of flying personnel (ibid).

The

most startling effect of atabrine is a yellow discolor
ation of the skin which occurs in the majority of persons
taklng suppressive doses.

This is not dangerous and

does not indicate liver damage.

The color goes in a

few weeks after atabrine is discontinued.
Again italicized (ibid):

"In spite of the

fact that publications from the Surgeon General's of
fice have repeatedly stressed that no drug is known
whieh w1ll act as a causal prophylaetie for malaria,
and that 'suppre-ssive treatment cannot be regarded as a
true control measure, misunderstanding on this subject
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persists in many quarters."
The military 1mportanee of that sentence has
been demonstrated by the experience of the

u.s.

forces

in tropical theaters. As one extreme example, an in
stance is cited (ibid) in which one unit fighting for
.five months in highly malarious territory and had a monthly malaria rate of about 1,000 eases per annum at the
time, despite the use of suppressive atabrine.
cases represented "break-throughs".

These

After the unit re

turned to a non-malarious base and the atabrine was
stopped, the malaria rate during the first month there�
after was 8,600 per annum, i.e., more than seventy percent of the men expertenoed a clinical attaek. Four
months later, relapse cases were occuring to such an
extent that the malaria rate of the unit was still
about 4,000 per annum, in spite of the fact that there
was no further exposure to the disease.

Therefore,

"suppressive treatment must be regarded only as a tem
porary expeni�nt to keep men on their feet during a
eampa1gn."
The effectiveness of at�br1ne in the sup
pression of malaria infection is still relative, but one
essential factoi►- is that_ the drug be_ ta�en regularly.
The higher dose (0.6 gram) is thought to be better than
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the smaller (0.4 gram} in that there are fewer •break
through" oases.

r-t is known that a certain per cent of

individuals will maintain a lower than average plasma.
level of the �drug, and this may predispose to clinical
eases.
The possibilities that continued administration
of atabrine might lead to drug resistant strains of
parasites and that suppressive treatment might be re
sponsible for a large number of relapses is purely specul
ative.

The suppressive treatment does not effect sub

sequent therapeutic atabrine.
"The entire picture regarding the prevention
of malaria would be changed by the discovery of a drug
which would act as a true causal prophylactic." (ibid}
PRESENT STATUS
The use of atabrine, quinine or plasmoohen
in the prevention of malaria should be considered only
as a suppressive measure, for these drugs will not pre
vent mosquito-borne malarial infections, but merely
suppress the clinical manifestations.
the

u.s. Army

Because of this,

regards the use of drugs as a temporary

expedient to keep men on their feet du.ring a campaign
in endemic areas of malaria.

The preferable procedure
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is to give 0.1 gm of atabrine six days a week, since
quinine is now unavailable.

SUMMARY OF THE PRESENT STATUS OF THE PROPHYLAXIS OF
DISEASE BY CHEMOTHERAPEUTIC AGENTS:
I.

Prophylactic use _of the sulfonamides.
A. In streptococcal infections 1n animals:
The exper1ments with laboratory animals have paved
the way for the clinical use of prophylaotiil sul
fonamides by offering proof that sufficient doses
of the drug can protect animals against lethal in
oculations of the hemolyt1� �treptoooocus.
B. In puerperal .fever:

The prophylactic use

of small doses (viz., one gram per day) o.f one ot

the sulfonamides will reduoe the chance ·of _post-

partum infection,.

The effectiveness of the drug is

�nhanced if the hemolytic streptococcus is the of
fending agent, and if the medication is begun short

ly after delivery and continued for at least four
days.

c.

In scarlet .fever:

A daily dose of one gram

of any of the soluble sulfonamides, espeetally sulfa
diazine, is extremely effective in protecting an in
dividual from a scarlet fever infection, the best
results bei� obtained if the drug is sta�ted a
few days before exposure.
D. In upper respiratory infections:
128A

The in_-
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gest�on of one gram of sulfad1az1ne each day will
greatly reduce the.chance of acquiring an upper
respiratory infection caused by the hemolytic strep
tococcus.

Epidemics of this condition may be eheok

ed by applying this plan to large numbers of people.
E. In rheumatie fever:

In patients who have

suffered from one or more rheumatie fever attacks,
the daily ingestion of one gram of sulf'adiazine
is extremely effective in preventing recrudescences.
The medication may be started about a month after
a rheumatic episode and continued indefinitely; a
common plan is to give the drug during the winter
months for five years.

There should be monthly

check-up� on the patient's progress, and the usual
control measures should not be discontinued.
F. In meningoooceic meningitis:

The menin

gocooei may be eliminated from the nasopharynx of
carriers by the ingestion of sulfadiazine, one gram
three times a day for three daya.

The same pro

cedure can also prevent elinical men1ngoeocc1 men
ingitis from appearing in almost all exposed cases.
G. In gonorrhea:

The chance

of acquiring a

clinical oaae of gonorrhea after exposure has been
shown to be greatly reduced by the 1nge-s·tion of .four
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to six grams of sulf'athiazole or sulfad1azine with
in twenty-rour hours after the oontaet.
H. In ehaneroid disease:

The chance of ac

quiring a che.ncroid infection af'ter exposure is
almost zero if four to six grams of sulfathiazole
or sulfadiazine are ingested within twenty-tour
hours.
I. In pneumoeocei pneumonia:

The chance of

acquiring a pneumococcic pneumonia. may be greatly
reduced by the daily ingestion of one gram of sulfa
diazine.
J.

In bae illa.ry dysentery:

Bacillary dysen

tery infeetions may be pr�vented by the ingestion
of 0.05 gm of su1tagu.anidine per kilogram of body
weight every four hours for three days after ex
posure.
K.

For external infections:

The usefulness

of oral administration of the sulfona.inide drugs to
prevent seoonds;ry infections in cases o:f burns,
wounds, and after surgery is as yet unprove� by
controlled series.
L.

In tuberculosis:

The use of the sul

fonamides in the prophylaxis of human tuberculosis
1s ineffectual and impractical.
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M.

In virus diseases:

In view of the work

on experimental animals, the use of proph,-laetie
sulfonamides 1n poliomyelitis or virus influenza
does not seem to be of any benefit in protecting ex
posed cases.

The prevention of measles by the drugs

is at present uneertain.
N.

Toxic reactions:

Using the most effective

prophylactic dose (one gram per day) and the least
toxic sulfonamide (sulfad1aztne), there may be ex
pected an ine�denoe

or 0.3 per cent to 0.6 per

cent toxie reactions.

About

o.oa

per cent will

have a dermatitis and 0.06 per cent a conjunctivitis.
About o.4 per cent will have •mild general" re
actions, with nausea, diarrhea, vomiting or faint
ness.

A.bout 0.024 per cent will have "severe gen

eral" reao.t1ons, with mental haziness, chills, fe
ver, edema, burning and itching.

About 0.012 per

cent will have "serious gen�ral" reactions with
fever, arthritis, edema, malaise, dizziness, ver
tigo, and collapse.
There should be no fa�alities if the dr�
is
: �
withdrawn immediately with toxic symptoms.

In

travenous dextrose and epine.phrine are efficacious
in treatment.
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Prophylactic sul.fonamides should be given on1y
under constant supervision, with routine examin
ation of the blood and urine.

o.

Phys1olog1eal effects:

In a fair per

centage of cases there are small cha,nges in visual
efficiency with the daily ingestiQn of one gram of
sulfadiazine or aulfathiazole, the former being less
obnoxious.

With most persons this ohange is not

great enough to call for a ehang� in daily routine,
but in extremely technical positions such as pi
lotingi caution should be used in the indtscrim•
inate use of these drugs.
There are no tangible changes from prophylaetie
doses· of sulfadiazine or sulfa thiazo-le on mental
efficienoy, heavy m�nual labor, or hand-$'f-$ coordin
ation.
P.

Acquired sensitivity:

The rate -0£ toxic

reactions with the second administration of the aul-
fonamide drugs is no gre�ter than that witn the
first administration.

The apparent sensitization

by small doses in certain reported cases has not
been substantiated by laboratory studies or in
large controlled series.
Q..

Production of drug-resis.tant baet.eria:

In
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some cases, sulfa-resistant bacteria have been
found in the throats of patients after small doses
of �ro��ylaetie sulfonamides.

The danger is in

creased with long and intensive medication.

In

other inatanees, there seems to be no foundation
for the £ear that soon all bacteria will become
sulfa-fast.
II..

Prophylactic use of the salicylates in rheumatie fever.
Rheumatic fever recrudescences may be pre
vented 1f every potential hemolytic streptocoecie
infection is recognized and then the patient given
four to six grams of aspirin daily for four weeks.
This should be continue� longer if the organisms
are still found in the throat.

III. Pro,hylactic use of Bayer 205 in trypanosomiasia.
An individual may obtain increased resistance

to trypanosome infections for a period of about

three months from one gram of Bayer 205 given in
travenously.

Because of the animal reservoir it

1a not �easible to eradicate the disease �roman
i�eeted area by mass. prophylaxis.
IV.

Suppression of malaria by drug prophylaxis.

The use of atabFine, quinine or plasmochen

in the prevention of malaria should be considered
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on1y as a suppre.ssive measure, for these drugs will
not prevent mosquito-borne malarial infections, but
merely suppress the clinical manifestations�
cause of this, the

u.s. Army

Bo

regards the use of

drugs as a temporary expedient to keep men on their
feet during a campa�gn in endemio areas of malaria.
1he preferable procedure is to give O.l gm of ata
brine six days a week, since quinine is Jdunavail�
able.
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